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1. Introduction  
 
1.1 Systemic lupus erythematosus 
 
Systemic lupus erythematosus (SLE) is a chronic immune disorder, classically depicted as 
a systemic autoimmune disease caused by the production of pathogenic autoantibodies to a 
spectrum of nuclear antigens. The clinical manifestations include immune complex-
mediated glomerulonephritis, arthritis, vasculitis, cerebritis, pericarditis, cytopenias and 
serositis [1]. SLE affects females more frequently than males, at a rate of almost 9 to 1; this 
would argue that female hormones might play a role in disease incidence. The prevalence 
of SLE ranges from approximately 40 cases per 100,000 persons among Northern 
Europeans to more than 200 per 100,000 persons among blacks [2]. However there is a 
wide variation in the prevalence of SLE worldwide, the highest prevalence was reported in 
Italy, Spain, Martinique, and the UK Afro-Caribbean population and shown in Figure 1. 
The recent advancements in understanding of molecular mechanisms involved in SLE 
pathogenesis have translated to development of new therapies [3]. These therapies have 
improved the life expectancy in lupus patients. However, there is a significant morbidity 
and mortality still remains in lupus patients. 
 
                            
Figure 1. Prevalence of Systemic lupus erythematosus. Population shown in thousands 
Taken From Nature Reviews Drug Discovery. 2008, 8: 103-104. 
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In SLE, nephritis is a leading cause of morbidity and mortality. It is referred as lupus 
nephritis (LN) and characterized serologically by a variety of autoantibodies to 
deoxyribonucleic acid (DNA), ribonucleic acid (RNA), other nuclear antigens (e.g. Smith, 
Ro, La) and cytoplasmic antigens. The presence of anti-dsDNA antibodies has been 
associated with disease activity [4, 5]. The clinical spectrum of LN ranges from mild 
urinary abnormalities to acute and chronic renal failure. Proteinuria present in almost every 
LN patient with nephritic syndrome [6]. Some of clinical features of lupus nephritis are 
mentioned in Table 1. Clinically, significant nephritis develops most commonly within 
three years after diagnosis. Mesangial and endocapillary hypercellularity, necrosis, crescent 
formation and granular deposition of immunoglobulin can observe in kidney biopsy 
sections of patients with lupus nephritis. The images of kidney sections were shown in 
Figure 2 [7]. 
 
 
Table 1. Clinical features of patients with lupus nephritis 
 
 
  
Adapted from J Am Soc Nephrol 1999, 10: 413–424. 
Feature % of nephritis 
Proteinuria                                                                                         100 
Nephrotic syndrome                                                                      45 to 65 
Granular casts                                                                                    30 
Red cell casts                                                                                       10 
Microscopic hematuria                                                                      80 
Macroscopic hematuria                                                                   1 to 2 
Reduced renal function                                                                  40 to 80 
Rapidly declining renal function                                                       30 
Acute renal failure                                                                           1 to 2 
Hypertension                                                                                   15 to 50 
Hyperkalemia                                                                                      15 
Tubular abnormalities                                                                   60 to 80 
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         A                                                        B    
Figure 2. Histopathological staining of kidney sections from lupus nephritis patient 
(A) PAS staining (B) IgG immunostaining 
Adapted and modified from N Engl J Med 1998; 339: 888-99. 
 
 
1.2 Pathogenesis of lupus 
 
The pathogenesis of lupus remains unclear, although several studies reported that defects in 
immune tolerance mechanisms and apoptosis explain how the immune system might 
recognize predominantly intracellular antigens. Several predisposing factors like genetic, 
hormonal and environmental factors also contribute to the disease pathology. The main 
focus of the thesis is studying immunological and molecular aspects that are involved in 
lupus pathomechanism, therefore predisposing genetic factors are not reviewed in this 
thesis. 
 
1.2.1 Cell death 
 
Cell death plays an important role in pathogenesis of SLE because it is the primary source 
for autoantigens. Cells can die through a number of different mechanisms. Two of the 
major types of cell death are apoptosis and necrosis [8]. Whether cells die through 
apoptosis or necrosis is determined by the initial stimulus and the microenvironment. 
Apoptosis is an active, programmed and regulated cellular process, which appears under 
both physiological and pathological conditions in all tissues. Morphologically, apoptotic 
cells shrink and at least initially maintain integrity of their plasma membrane. In contrast, 
necrotic cell death occurs in response to many kinds of insults (e.g., trauma, infarction, 
toxins, etc.) and therefore is typically the result of a pathological process [9]. 
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Morphologically, it is associated with cell swelling and the rapid loss of membrane 
integrity. The host responses to these two forms of cell death are different. Apoptotic cell 
death does not provoke inflammation [10], for example, there is continuous death of 
developing T cells in the thymus, and this occurs without inducing an inflammatory 
response. In contrast, necrotic cell death stimulates a host inflammatory response. 
Morphological and biochemical changes of dying cells are extremely important for their 
clearance from tissues by the scavenger system. Disordered regulation of both apoptosis 
and the clearance of apoptotic products have been implicated in the pathogenesis of SLE 
[11]. Under normal circumstances, activity against self antigens is prevented by several 
mechanisms, including the Apo-1/Fas pathway of apoptosis, which maintain immune 
tolerance by deleting unwanted autoreactive T cells and B cells [12]. Defect in this Fas 
pathway lead to accumulation of lymphocytes, particularly autoreactive lymphocytes. This 
is the basic mechanism by which Fas-deficient MRLlpr/lpr mice develop an autoimmune 
syndrome.  
 
There is growing evidence for the concept that a clearance deficiency of apoptotic cells can 
lead to lupus in mouse models [13, 14] and in humans [15, 16]. Primary necrotic cells and 
secondary necrotic cells (cells that can’t undergo apoptosis) release molecules for example 
DNA-containing nucleosomes, high mobility group B1 (HMB1) protein, heats hock 
proteins and uric acid. Collectively these self derived antigen molecules are termed as 
damage-associated molecular patterns (DAMPs). Among these nucleosomes are best 
studied in pathology of SLE. SLE patients have greater levels of circulating nucleosomes 
than the healthy individuals. 
 
1.2.2 Nucleosomes 
 
Nucleosomes are complexes of DNA and histones around which double stranded DNA 
(dsDNA) was wrapped twice. Several studies suggest that autoantibody interactions occur 
with nucleosomes. Antibodies reactive to nucleosomes have been detected both in SLE 
patients and in murine lupus models, even prior to the development of anti-dsDNA and 
antihistone antibodies [17]. These antibodies can bind to the glomerular basement 
membrane via nucleosomes [18], [19]. Nucleosomes and intracellular debris appear as 
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blebs on apoptotic cell surfaces, and might incite T cell-driven stimulation of B cells. The 
injection of syngeneic apoptotic cells into normal mice trigger the antinuclear antibodies 
and immune deposition in kidneys [20]. Nephritogenic lupus antibodies directly bind to 
glomerular basement membrane-associated chromatin fragments released from apoptotic 
intra glomerular cells [21, 22]. Furthermore, terminal deoxynucleotidyl-transferase (TdT)-
mediated dUTP nick end-labeling (TUNEL) assay and activated caspase 3 staining 
demonstrated the accumulation of apoptotic cells in glomeruli and chromatin in glomerular 
capillary membranes and in the mesangial matrix. These data suggest that apoptotic 
nucleosomes can be released and bound to glomerular membranes. Later pathogenic anti-
nucleosome antibodies bind to these glomerular membranes and initiate pathological events 
such as induction of inflammatory cytokines and mesangial cell proliferation. Finally, this 
leads to kidney damage. 
 
Nucleosomes and other self antigens are internalized by antigen presenting cells (APC), 
such as, dendritic cells (DCs), macrophages and B cells. After internalization, APC present 
self antigens to CD4+ T cells via MHC class II molecule. This is the mechanism how self 
antigens activate the adaptive immune system in lupus. In adaptive immunity T and B cell 
are involved. However, self antigens can directly activate APC to release inflammatory 
cytokines via pattern recognition receptors. All these events are discussed in the following 
sections. 
 
1.2.3 T and B lymphocytes 
 
In lupus dsDNA-IgG high-affinity antibodies are strongly associated with tissue damage 
[5]. Production of these high-affinity IgG antibodies is driven by antigen, a process in 
which antigen binds to B lymphocytes, thereby stimulating the cells to proliferate. This 
antigen-driven process can occur only in B lymphocytes that are being stimulated by T 
helper lymphocytes as well as by antigen. This process is known as T lymphocyte help. 
Each T cell carries a surface-receptor molecule; it interacts with one particular antigen, 
generally complexed with an MHC molecule on the surface of an APC. Along with 
presentation of the antigen–MHC complex to T cell, APC also make another costimulatory 
signal to fully activate T cells. There are different costimulatory molecular pairs, including 
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the CD40–CD40 ligand and CD28–B7, which can activate T cells. Agents that block 
costimulation, for example anti- CD40 ligand [23] and cytotoxic T-lymphocyte–associated 
protein 4 IgG1 (CTLA-4–Ig) [24], a molecule that blocks the CD28–B7 interaction, are 
potential treatments for lupus. B cell and T cell interact and stimulate each other. T-cell 
cytokines can stimulate cell division of B cells, switching antibody production from IgM to 
IgG [25], so that it binds more strongly to the antigen [26]. Thus, T-cell help fosters the 
production of high-affinity IgG autoantibodies. These kinds of antibodies are closely linked 
to tissue damage in lupus. One study documented the significance of nephritogenic T cells 
in renal disease [27]. They generated MRL/lpr mice deficient in serum immunoglobulin but 
expressing a membrane bound anti-(4-hydroxy-3-nitrophenyl) acetyl transgenic antibody. 
These mice developed glomerulosclerosis and interstitial nephritis, showing that renal 
immune complexes were not required for chronic renal disease. T cell infiltration in 
kidneys is seen with increasing severity of glomerulonephritis in mouse models [28]. 
Regulatory T cells, one type of T cells suppress the activation of helper T cells and B cells 
in humans and mice. Some studies have reported a reduction in the number or function of 
regulatory T cells in patients with lupus and in lupus prone mice [29, 30]. Regulatory T 
cells from patients with active lupus have a reduced ability to suppress the proliferation of 
helper T cells, as compared with regulatory T cells from patients with inactive lupus or 
healthy controls [30]. All these data support the hypothesis that kidney reactive T cells play 
a direct role in pathogenesis of glomerulonephritis. 
 
That B cells contribute to the pathogenesis of lupus nephritis is increasingly appreciated in 
many other ways. They function as potent antigen-presenting cells, this role and their 
ability to clonally expand makes them highly efficient activators of antigen-specific T cells. 
More recent evidences suggest that B cells also play a role in the production of 
lymphangiogenic factors; thus, the B cell may orchestrate the local expansion of 
lymphatics required to support a florid immune response. Furthermore, B cells regulate T 
cells and DCs through the production of cytokines or regulatory antibodies. B cells 
producing autoantibodies in SLE have undergone extensive clonal expansion, suggesting 
that these antibodies are produced in response to chronic stimulation of B cells by antigen 
and costimulatory autoreactive CD4 T cells. Another B-cell-related functions likely to be 
 6
important in the pathogenesis of SLE is cytokine release, particularly proinflammatory 
cytokines IL-12, tumor necrosis factor (TNF)-α, and IL-6, all of which are produced in 
high levels in SLE. BlyS/BAFF (B lymphocyte stimulator/B-cell activating factor), a TNF-
family cytokine that promotes B-cell maturation, survival and plasma cell differentiation 
also produced high levels in SLE. [31]. The role of the B lymphocyte as an APC is also 
likely to be essential in the development of autoimmunity. In experimental models of 
autoimmune arthritis, the APC function of B cells is essential for the development of 
disease, while the antibody-secreting function is not [27, 32].  
 
1.2.4 Autoantibodies 
 
Kidneys from patients with lupus nephritis were shown to contain antibodies that bind 
native, dsDNA [33]. The importance of anti–dsDNA antibodies in the pathogenesis of 
lupus has been confirmed [34]. Anti–dsDNA antibodies are hallmark for lupus, 70% of 
lupus patients are positive for these antibodies. In many patients with SLE, increased renal 
disease activity is associated with rising titres of anti-DNA antibodies. Antibodies to single 
stranded DNA (ssDNA) and dsDNA are part of the normal repertoire of natural 
autoantibodies; most of these are low-affinity IgM antibodies that react weakly with several 
self-antigens. However, these natural antibodies can undergo an isotype switch (from IgM 
to IgG) that increases their pathogenic potential. In addition, somatic mutations in the 
encoding immunoglobulin genes can result in the production of high-affinity IgG 
antibodies to DNA. Several other autoantibodies are also present in SLE for example anti-
Sm, anti-RNP, anti-Ro and anti-La etc. However the role of these antibodies in disease 
progression is uncertain [6]. Different types of autoantibodies present in lupus patients are 
shown in table 2. 
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Table 2. Autoantibodies present in lupus patients  
 
 
 
Adapted from J Am Soc Nephrol 1999; 10: 413–424. 
Autoantibody 
Anti-DNA antibodies 
 
   anti-ds (native)DNA                         40 to 90                             High                                    Yes                     
 
   anti-ss(denatured)DNA                        70                                  Low                                     No 
 
   anti-histone                                           70                                  Low                                     No  
                    
   anti-nucleosome                                     80                                 Low                                     No 
 
Anti-ribonucleoprotein antibodies 
 
   anti-Sm                                              5 to 30                              High                                     No 
 
   anti-U1-RNP                                   25 to 35                              Low                                      No 
 
   anti-SSA/Ro                                         35                                  Low                                      No                    
 
   anti-SSB/La                                         15                                   Low                                      No                    
                                                                                                                                         
 
   antiribosomal P protein                     25 to 35                            Low                                     No                           
 
Other antibodies 
 
   anti-C1q                                            80 to 100                          High                                     Yes              
 
   anti-hsp90                                             25                                 Low                                      No              
 
 
antiphospholipidd                                25 to 50                            Low                                       No           
 
   anti-RA33                                        20 to 40                           Low                                     No                  
Association with 
Disease Activity 
Diagnostic 
 Specificity 
Frequency (%) in 
Untreated Patients 
with Lupus 
 
 
Anti-dsDNA antibodies can mediate tissue damage in lupus patients. There are two models 
proposed; both models state that, the binding of antibodies to dsDNA itself is not the most 
critical determinant of tissue damage. When cells undergo apoptosis, they release 
chromatin fragments, which are the main source for extracellular dsDNA and nucleosomes. 
In one study it was proposed that pathogenic anti–dsDNA autoantibodies in patients with 
lupus bind to nucleosomes that have entered the bloodstream, then these antibody–
nucleosome complexes settle in the renal glomerular basement membrane [35]. These 
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immune complexes activate complement, which initiates the glomerulonephritis. This was 
demonstrated in animal models [36, 37]. Supporting this anti-nucleosome antibodies found 
in the blood and inflamed tissues of patients with lupus [38]. In second model anti–dsDNA, 
anti-nucleosome antibodies, or both cross-react with proteins in the kidney; thus, they have 
a direct pathogenic effect on renal cells. This is an example of polyreactivity, whereby the 
same antibody can bind to antigens with different structures because they have similar 
shared epitopes. Finally in lupus the deposition of immunoglobulins within the glomerular 
and tubular basement membranes leads to local inflammatory responses that ultimately 
cause renal fibrosis.  
 
1.2.5 Type 1 interferons and other proinflammatory cytokines 
 
Interferons (IFNs) and proinflammatory cytokines play an active role in the pathogenesis of 
SLE and can contribute significantly to the immune imbalance in the disease. The type I 
IFN family consists subtypes of α-IFN and the single β-IFN [39]. Increased levels of IFN-α 
in the serum of lupus patients were first noted over 30 years ago [40] and subsequently 
confirmed in several studies [41]. Surprisingly, an increase in IFN-α is not associated with 
a consistent increase in IFN-β, because of their independent regulation. Although other 
cytokines are also increased in lupus sera, IFN-α levels best coincide with disease 
exacerbations [42]. Sometimes IFN-α treatment (for viral infections, tumours) also 
exacerbates or even induces a wide spectrum of autoimmune manifestations, including 
lupus [43]. The role of IFN-α in pathogenesis of lupus was substantiated by the recent 
finding that sera from lupus patients induced maturation of normal blood monocytes into 
efficient antigen-presenting DCs, and the active factor for this effect was IFN-α [44]. In 
addition to that, microarray studies with peripheral blood mononuclear cells of lupus 
patients showed increased signatures of IFN-α- and IFN-γ [39]. Recent microarray analysis 
of laser-captured glomeruli from lupus patients showed type I IFN response elements 
among the four dominant clusters of over expressed genes, whereas IFN-γ -induced 
transcripts were less prominent [45].  
 
Why lupus patients have higher levels of IFN-α has not been fully explained, but both 
exogenous and endogenous inducers may play a role (Figure 3). As exogenous inducers, 
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viral components may be the culprits, IFN-α/β production may be a common pathway by 
which infection by a variety of pathogens can induce or exacerbate systemic autoimmunity 
in susceptible individuals, as often seen in SLE following infection. However, there is also 
evidence for endogenous IFN-α/β inducers, such as products of apoptotic or necrotic cells 
combined with lupus serum autoantibodies [46]. Anti-DNA and anti-ribonucleoprotein 
(anti-RNP) complexes with DNA or RNA, respectively can stimulate IFN-α/β production 
through Fcγ RIIa binding and internalization [47]. This finding is consistent with the recent 
suggestion that mammalian RNA and DNA, which is capable of binding to IFN-α/β-
inducing endosomal TLRs. Thus, only the anti-RNP/RNP complexes, taken up in the 
endosomes, could result in activation of the relevant TLRs and production of IFN-α/β. 
IFNAR1-deficient NZB lupus mice showed significant reduced disease pathology [48].In 
addition to NZB mice, disease reduction was reported in IFNAR1-deleted B6.Faslpr mice 
[49] but, surprisingly, not in similarly deleted MRLlpr/lpr mice [50]. No clear reason was 
reported for these opposite responses. Because IFNs exert potent pleiotropic effects, their 
role as pathogenic effectors in this disease is likely to be mediated by multiple mechanisms 
(Figure 3), including enhanced DC maturation and self-Ag presentation; promotion of T 
and B cell differentiation, proliferation, and survival Disturbances in the balance of anti- 
and proinflammatory cytokines; and induction of chemokines and their receptors promote 
homing of inflammatory cells in tissues. Overall, IFN-α/β signaling appears to be a master 
switch that activates all or most of the above pathways, leading to pathogenicity in lupus-
predisposed backgrounds. 
 
Other cytokines are also involved in pathogenesis of lupus. The role of TNF-α in lupus is 
controversial. This cytokine may be protective in patients with lupus, since giving TNF-α 
to lupus-prone NZB/W F1 mice delayed the development of lupus [51]. The protective 
effect is specific to that mouse strain, and the mechanism is unknown. In some patients 
with rheumatoid arthritis who were treated with anti–TNF-α developed anti–dsDNA 
antibodies [52], and lupus erythematosus in a few of these patients [53]. IL-6 is yet another 
important cytokine, which induces the expression of acute phase proteins and also leads to  
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Figure 3. Mechanisms by which IFN-α/β may contribute to the pathogenesis of systemic and organ-
specific autoimmune diseases in predisposed backgrounds. 
Taken from Annu Rev Immunol 2005, 23: 307-36. 
 
 
increased antibody secretion by B-lineage cells [54].TGFβ could exert a bi-directional 
effect similar to the effects of the classical Th2 cytokines, with less inflammation on the 
one hand, but more fibrosis on the other hand. TGFβ may also play a role for regulatory T 
cell action. Increased glomerular TGFß was found in samples of adults as well as children 
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with lupus nephritis [55]. In MRLlpr/lpr mice, TGFß is over expressed, additional TGFβ is 
beneficial with regard to autoantibody formation, kidney disease and survival [56], but its 
role in fibrosis has been suggested to be critical. 
 
1.3 Pattern recognition receptors  
 
The mammalian immune system is divided into innate and adaptive immunity, and co-
operative interactions of both are required for elimination of infective pathogens with the 
highest efficiency. The innate immune system is an evolutionarily conserved system that 
provides the first line of protection against invading microbial pathogens and is mediated 
by macrophages, dendritic cells, neutrophils, natural killer cells, basophils, mast cells and 
eosinophils [57-60]. These cells sense microbial infection and induce inflammatory 
responses. Innate immune system senses microbial infection using ‘pattern recognition 
receptors (PRRs)’ that recognize ‘pathogen-associated molecular patterns (PAMPs) [61]. 
Because PAMPs are broadly expressed in pathogens but not in host cells, PRRs 
discriminate between self and non-self. PRR activation can differentially modulate immune 
responses in cases of infection and autoimmune disorders. Among these receptors are Toll 
like receptors (TLR), nucleic acid specific-cytosolic receptors (RIG like helicases) and 
NOD like receptors [58]. 
 
1.3.1 Toll like receptors 
 
TLRs are type I membrane-spanning non catalytic receptors and consist of an extracellular 
LRR (leucine-rich repeat) domain, a transmembrane domain and a cytoplasmic TIR 
(Toll/interleukin-1 receptor) domain [62]. The LRR domain of TLRs consists of 16–28 
tandem repeats of the LRR motif [63] and mediates the recognition of ligands. The TIR 
domain of TLRs consists of approx. 150 amino acids and shows homology with the 
cytoplasmic region of the IL-1 receptor [64]. The TIR domain interacts with TIR-domain-
containing adaptors such as MyD88 (myeloid differentiation primary response gene 88), 
TIRAP (TIR-containing adaptor protein), also known as MAL (MyD88-adaptor-like), 
TRIF (TIR-containing adaptor-inducing IFN interferon-β), also known as TICAM1 (TIR-
domain containing adaptor molecule 1) and TRAM (TRIF-related adaptor molecule), also 
known as TICAM2. The cellular localization of the TLRs has important consequences for 
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ligand accessibility and can also affect downstream signaling events. The TLRs involved in 
the recognition of nucleic acids (TLR3, TLR7, TLR8 and TLR9) are localized within 
endolysosomal compartments, whereas other TLR family members (TLR1,TLR2, TLR4, 
TLR5 and TLR6) are found at the cell surface [65]. TLRs, their recognition molecules and 
their adaptor molecules are mentioned in Table 3 and signaling pathways shown in Figure 
4. The thesis main focus is nucleic acid recognition receptors so TLRs which recognize non 
nucleic acid molecules are not reviewed here. 
 
TLR3 
TLR3 recognizes viral dsRNA from dsRNA viruses such as reovirus and dsRNA produced 
during replication of ssRNA viruses, such as West Nile virus and RSV [66, 67]. In 
addition, poly (I:C) a synthetic analogue of dsRNA can also recognized by TLR3 (Table 3). 
TLR3 is expressed in the endosomal compartments of immune cells, including cDCs 
(conventional DCs), macrophages, B-cells, NK cells and non-immune cells, including 
epithelial cells. However pDCs (plasmacytoid DCs) don’t express TLR3. TLR3 is 
dispensable for protection against various RNA viruses such as murine cytomegalovirus, 
vesicular-stomatitis virus, lymphocytic choriomeningitis virus, RSV and reovirus [68]. 
Therefore, the role of TLR3 in viral infection is unclear. 
 
TLR7/8 
TLR7 is responsible for the imidazoquinoline-induced immune responses [69]. TLR7 also 
recognizes guanosine- or uridine-rich ssRNA from viruses such as human 
immunodeficiency virus, vesicular stomatitis virus, and influenza virus (Table 3). The 
ssRNA is also produced within the host, but it is not recognized by TLR7 under normal 
conditions, may be this is explained by the unique distribution of TLRs. TLR7 is expressed 
in the endosomal membrane and self-derived ssRNA cannot reach to this compartment. 
TLR8 is homologous to the TLR7. Human TLR8 has been shown to recognize the 
imidazoquinolines and ssRNA, which are the ligands for TLR7. In contrast, mouse TLR8 
expressed in different cells but does not recognize these TLR7 ligands, it indicates that 
mouse TLR8 is nonfunctional. Human TLR8 is expressed in regulatory T cells (Treg), and 
activation of TLR8 inhibits Treg function [70]. 
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Table 3. PRRs and PAMPs 
         PRRs                          Adapters PAMPs/Activators  Species 
TLR   TLR1–TLR2 (LRR–TIR)       MyD88 (TIR–DD),            Triacyl lipopeptides   Bacteria 
                                                           TIRAP (TIR) 
           TLR2–TLR6 (LRR–TIR)       MyD88 TIRAP                   Diacyl lipopeptides               Mycoplasma 
                                                                                                       LTA                                      Bacteria 
                                                                                                       Zymosan                               Fungus 
            TLR2 (LRR–TIR)                  MyD88, TIRAP                  PGN                                    Bacteria 
                                                                                                       Lipoarabinomannan             Mycobacteria 
                                                                                                       Porins                                  Bacteria 
                                                                                                       tGPI-mucin                          Parasites 
                                                                                                       HA protein                           Virus 
            TLR3 (LRR–TIR)                 TRIF (TIR)                         dsRNA                                 Virus 
            TLR4 (LRR–TIR)                  MyD88, TIRAP, TRIF,      LPS                                      Bacteria 
                                                           TRAM (TIR)                      Envelope proteins                 Virus 
            TLR5 (LRR–TIR)                  MyD88                              flagellin                                 Bacteria 
            TLR7 (LRR–TIR)                  MyD88                              ssRNA                                   RNA virus 
             hTLR8 (LRR–TIR)               MyD88                              ssRNA                                   RNA virus 
            TLR9 (LRR–TIR)                  MyD88                              CpG DNA                             Bacteria 
                                                                                                      DNA                                      DNA virus 
                                                                                                      Malaria hemozoin                 Parasites 
             mTLR11 (LRR–TIR)            MyD88                              Not determined                     Bacteria 
                                                                                                      Profilin-like molecule           Parasites 
RLR     RIG-I (CARDx2–helicase)   IPS-1 (CARD)                  RNA (5’-PPP ssRNA,           Virus 
                                                                                                      short dsRNA) 
             MDA5 (CARDx2–helicase)  IPS-1                                 RNA (poly IC)                      Virus 
             LGP2 (helicase)                                                               RNA                                      Virus 
             NLR NOD1/NLRC1             RICK (CARD), CARD9   iE-DAP                                 Bacteria 
                                                                 (CARD)   
             NOD2/NLRC2                     RICK, CARD9                   MDP                                     Bacteria 
             NALP3/NLRP3                   ASC (PYD–CARD)            MDP                                     Bacteria 
                                                          CARDINAL (PYD–FIND)  RNA                                    Bacteria, Virus 
                                                                                                       ATP                                     Bacteria? Host? 
                                                                                                       Toxins                                Bacteria 
                                                                                                       Uric acid, CPPD,               Host 
                                                                                                       amyloid-b 
            NALP1/NLRP1                              ASC                            Anthrax lethal toxin           Bacteria 
            (CARD–FIND–NBD–LRR-PYD)                 
            IPAF/NLRC4 (CARD–NBD–LRR)                                 Flagellin                              Bacteria 
            NAIP5 (BIRx3–NBD–LRR)                                             Flagellin                             Bacteria 
Taken from International Immunology 2009, 21: 317–337. 
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Figure 4. Signaling mediated by TLR is broadly classified as MyD88-dependent and independent 
pathways. See the text for detailed description. 
Taken from Experimental and molecular medicine 2007, 39: 421-438. 
 
TLR9 
TLR9 recognize CpG motif of bacterial and viral DNA (Table 3). TLR9 knockout mice 
does not show any response to CpG DNA [71]. In vertebrates, the frequency of CpG motifs 
are less and the cysteine residues of the CpG motifs are highly methylated, because of this 
vertebrates DNA loss the immunostimulatory activity. There are two types of CpG DNA, 
CpG-A and CpG-B, both of which are recognized by TLR9. CpG-B is the conventional 
type, and it is a potent inducer of inflammatory cytokines such as IL-12 and TNF-α. CpG-
A is structurally different from CpG-B and has a greater ability to induce IFN-α production 
from pDCs, but a lesser ability to induce IL-12 [72]. Differential patterns of cytokine 
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induction by both CpG DNAs are now explained by the retention of CpG-A in the 
endosome of pDCs that induce activation of the MyD88-IRF7 pathway essential for IFN-α 
induction [73]. 
 
TLR signaling 
Signaling through TLR recruits various TIR-domain-containing adaptors to the TIR 
domain of TLRs. TLR7, TLR8 and TLR9 use only MyD88. TLR3 only uses TRIF (Figure 
4) [58, 64, 74]. In the MyD88-dependent signaling pathway, the IRAK (IL-1 receptor-
associated kinase) family members, such as IRAK4, IRAK1 and IRAK2 are recruited to the 
MyD88. IRAK4 is initially activated and IRAK1 and IRAK2 are sequentially activated 
[75]. The activated IRAK family proteins associate with TRAF6 (TNF receptor-associated 
factor 6). This complex polyubiquitinates TRAF6 itself and IKKγ (IκB kinase γ), also 
known as NEMO (NF-κB essential modifier) through K63 (Lys63) linkage. The 
polyubiquitinated TRAF6 activates the protein kinase TAK (transforming growth factor-β-
activated kinase 1) and TABs (TAK1-binding proteins) such as TAB1, TAB2 and TAB3, 
which subsequently activate transcription factors such as NF-κB and AP-1 (activator 
protein-1) through the canonical IKK complex and the MAPK, ERK (extra cellular-signal-
regulated kinase), JNK (c-jun N-terminal kinase) and p38 pathway respectively for the 
transcription of inflammatory cytokine genes [76].  
 
Stimulation with TLR3 ligands activates the TRIF-dependent signaling pathway and 
induces inflammatory cytokines in addition to type I IFNs and IFN-inducible genes in DCs 
and macrophages, which depend on IRF3 and IRF7 [77]. IRF3 and IRF7 are activated by 
IKK-related kinase TBK1 (TANK binding kinase 1) [78, 79]. TBK1 and IKKi interact with 
TANK (TRAF family member-associated NF-κB activator) which then phosphorylates 
IRF3 and IRF7. Phosphorylated IRF3 and IRF7 form a homodimer, which subsequently 
translocates into the nucleus and binds to the ISREs (IFN-stimulated response elements) to 
induce type I IFNs and IFN-inducible genes (Figure 4). In pDCs, TLR7 and TLR9 are 
highly expressed and induce a huge amount of type I IFNs, particularly IFN-α, after virus 
infection. Upon stimulation, MyD88 forms a complex with IRF7 [73, 80] (which is highly 
expressed in pDCs) and TRAF6 to induce the production of type I IFNs. IRAK1 interacts 
with MyD88 and can phosphorylate IRF7 [81]. IRAK1-deficient pDCs consistently have 
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defects in type I IFN production, but show intact inflammatory cytokine production. Taken 
together, these observations suggest that the TLR7 or TLR9 signaling pathway is active in 
pDCs for the robust production of type I IFNs after virus infection (Figure 4). 
 
1.3.2 Cytosolic nucleic acid pattern recognition receptors 
 
Rig-I-like receptors 
 
There are three members of RLR family, Retinoic acid-inducible gene 1(RIG-1), melanoma 
differentiation associated gene 5 (MDA5) and laboratory of genetics and physiology 2 
(LGP2)— These receptors recognize viral RNA in the cytoplasm (Figure 5) [82]. 
 
1 678 
10251 
925 Helicase domainCARD RD 
RIG-1 
MDA5 
LGP2  
 
Figure 5. Structure of RIG-I family helicases. The RIG-I family consists of RIG-1, MDA5 and LGP2. 
 
RIG-1, a prototypical member of the RLR family, contains tandem caspase recruitment 
domain (CARD)-like regions at its N-terminus that function as an interaction domain with 
other CARD-containing proteins, the central the DExD/H helicase domain, which has an 
ATP-binding motif (Figure 5). RIG-1 also has a C-terminal repressor domain (RD), which 
binds to RNA [83, 84]. Normally, RIG-1 is inactive as a monomer, but viral infection or 
RNA binding trigger conformational changes to facilitate self-association, which promotes 
CARD interaction with downstream signaling molecules. MDA5 contains tandem CARD-
like regions and a DExD/H helicase domain, but it is unknown whether the C-terminal 
region of MDA5 really functions as an RD. LGP2 contains a DExD/H helicase domain and 
an RD, but lacks the CARD-like region (Figure 5). LGP2 is a negative regulator of RNA 
virus-induced responses, because the LGP2, RD binds to that of RIG-I and suppresses 
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signaling by interfering with the self-association of RIG-I. Knock out mice data showed 
that [85, 86]. RIG-I is essential for the recognition of various ssRNA viruses, which include 
paramyxoviruses, influenza A virus, VSV and Japanese encephalitis virus. 
 
MDA5 is required for the recognition of other RNA viruses, including picornaviruses such 
as EMCV, Mengo virus and Theiler’s virus; moreover, MDA5 is involved in the 
recognition of poly I:C. These findings suggest through recognition of distinct structures of 
viral RNA might be the reason that RIG-I and MDA5 can detect different RNA viruses. 
This is likely because RIG-1 is activated following transfection of in vitro transcribed 
RNA, whereas MDA5 is activated by poly I:C. RIG-1 recognize ssRNA bearing a 
5’triphosphate moiety [87, 88]. 5’-triphosphate structures are removed or masked by a cap 
structure in the case of self-RNA. This demonstrates a discrimination mechanism between 
self and non-self RNA; however, the 5’-triphosphate structure is necessary but not 
sufficient for RIG-1 recognition. Later it was shown that  RIG-1 recognition is determined 
by a homopolymeric ribonucleotide composition such as the polyuridine motif of the 
hepatitis C virus (HCV) genome 3’non-translated region, by linear RNA structure and by 
RNA length [89] and also it was shown that RIG-1 recognizes small dsRNA species 
ranging from 21 to 27 nucleotides without a 3’-overhang [90]. RIG-1 and MDA5 
distinguish dsRNA by size; RIG-1 binds short dsRNA, whereas MDA5 binds long dsRNA 
[91]. Initially LGP2 implicated as a negative regulator, but LGP2- deficient mice exhibit 
complicated phenotypes [92]. They show elevated levels of type I IFN in response to poly 
IC and VSV, but decreased type I IFN following EMCV infection, suggesting that LGP2 
negatively or positively regulates RIG-I and MDA5 responses, depending on the type of 
RNA viruses. 
 
In RLR signaling, after the ligand binding to the receptors, they activate NF-kB, MAPK 
and IRFs for induction of type I IFN and inflammatory cytokines. IFNβ promoter 
stimulator 1 (IPS-1), also known as mitochondrial anti-viral signaling (MAVS), CARD 
adapter inducing IFNβ (Cardif) or virus-induced signaling adapter (VISA) is the adapter for 
RIG-I and MDA5 (Figure 6) [93-96]. IPS-1 contains an N-terminal CARD-like domain and 
a transmembrane domain at the C-terminal end. CARD like domain is responsible for the 
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interaction with RLRs and transmembrane domain is required for mitochondrial targeting 
as well as triggering anti-viral responses. NS3/4A serine protease in HCV cleaves IPS-1. It 
suggests that HCV utilizes NS3/ 4A as a strategy to evade host anti-viral responses. IPS-1 
recruits TRADD, which in turns assembles with Fas-associated death domain protein 
(FADD) and RIP-1 [94, 97]. Caspase-8 and caspase-10 are then recruited to FADD, where 
they are processed and activate NF-kB. TRADD forms a complex with TRAF3, then it 
induces TBK1–IKKi-dependent IRF3 activation. STING is also involved in RIG-1 
signaling (Figure 6). STING interacts with RIG-1 but not MDA5, and cells lacking STING 
showed attenuated type I IFN induction following infection with VSV. TLR signaling was 
unimpaired by STING deficiency. Similar to STING, mediator of IRF3 activation (MITA) 
also participates in RLR signaling. TRIM25 is another protein, which directly binds to 
RIG-1 and promotes Lys-63-linked ubiquitination of the CARD of RIG-1, which facilitates 
the recruitment of IPS-1 to activate signaling. TRIM25-null cells consistently display a loss 
of RIG-I ubiquitination as well as impaired anti-viral responses [98]. 
 
 
Figure 6. RLR signaling pathway. See the text for description 
Taken from Biochem. J 2009, 420: 1–16. 
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DNA recognition by cytosolic receptors 
 
TLR 9 recognizes CpG DNA, however dsDNA without CpG motifs derived from host or 
pathogens can initiate strong immune response, but ssDNA failed to activate immune 
responses [99-101]. This effect was observed when DNA transfected inside dendritic cells, 
macrophages and nonimmune cells such as epithelial cells, fibroblasts, and thyroid cells 
can induce production of type I IFNs through recognition pathways independent of TLR9 
[101]. The dsDNA recognition occurs similar to RLRs via TBK1, a protein kinase that 
phosphorylates the transcription factor IFN regulatory factor (IRF) 3 (Figure 7), in contrast 
TLR9 triggers type I IFN without TBK1. Whereas right-hand B-form of dsDNA shows 
high immunostimulatory activity with regards to cytokine induction compare to the left-
hand Z-form dsDNA or ssDNA has low or no activity [100]. RNA interference analysis 
clearly demonstrated that signaling adaptor IPS-1and RIG- were involved in B-DNA-
mediated signaling in human cells [102]. However, IPS-1-/- or RIG-I-/- mouse embryonic 
fibroblasts (MEFs) responded similar to wildtype cells for B-DNA stimulation. The 
response was completely abrogated in TBK1-/- MEFs, suggesting that species-specific 
signaling pathways exist [103, 104]. 
 
Several molecules were screened to identify cytoplasmic DNA receptors, among these 
DNA-dependent activator of IRF (DAI, also known as Z-DNA-binding protein 1 and 
DLM1) has been isolated as a DNA sensor with DNA-binding and TBK1-activating 
properties [105]. However, responses against dsDNA were unaffected by DAI deficiency in 
mice, suggesting a redundant or non-essential role of DAI [106]. Recently, stimulator of 
IFNgenes (STING), a membrane protein predominantly expressed in the ER, has been 
identified [107]. STING-deficient cells showed diminished type I IFN induction following 
cytosolic dsDNA stimulation. Caspase-1 regulates the B-DNA-mediated production of IL-
1β, IL-18, and IL-33. PYHIN (pyrin and HIN domain-containing protein) family member 
absent in melanoma 2 (AIM2) was also identified as a receptor for cytosolic DNA, which 
regulates caspase-1[108]. The HIN200 domain of AIM2 binds to DNA, whereas the pyrin 
domain (but not that of the other PYHIN family members) associates with the adaptor 
molecule ASC (apoptosis-associated speck-like protein containing a caspase activation and 
recruitment domain) to activate both NF-kappaB and caspase-1. But AIM2 is not 
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responsible for B-DNA induced interferon signaling [108-112]. Recently, it was shown that 
polymerease III plays a role in poly (dA:dT) signaling. AT-rich dsDNA served as a 
template for RNA polymerase III and it transcribed into dsRNA containing a 5'-
triphosphate moiety. Then this dsRNA activate RIG-1 pathway for the production of type I 
interferon and activation of the transcription factor NF-kappaB. Other format of B-DNA 
are independent of polymerase III and this system exist in humans only [113]. 
 
 
Figure 7. Cytosolic DNA signaling pathways 
Taken from Cell, 2009, 138: 428-430 
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1.3.3 The inflammasome 
 
The Inflammasome is one of the subgroup in NLR family proteins. It is involved in 
processing of cytokines belongs to IL-1 family. The IL-1 family of cytokines, includes IL-
1β, IL-18 and IL-33, which are key cytokines that regulate various components of innate 
and adaptive immunity. The production of these cytokines is regulated by two signals in 
innate immune cells (e.g. macrophages). The first signal comes from various TLR, NLR 
and RLR agonists and the second signal comes from the inflammasome. The type of 
inflammasomes are NALP3 (NACHT [NTPase-domain named after NAIP, CIITA, HETE 
and TP1]–LRR-PYD–containing protein 3), NALP1 (also known as NLRP1), or NLRC4 
(also known IL-1β-converting-enzyme protease-activating factor [IPAF]). Recently, the 
protein AIM2 was shoen to assemble an inflammasome (Figure 8) [114]. The NALP3 
inflammasome is activated by various exogenous and host endogenous ligands. Exogenous 
ligands include microbial ligands such as MDP, bacterial and viral RNA, toxins such as 
nigericin, maitotoxin, environmental pollutants such as asbestos and silica [115] and 
vaccine adjuvant alum (aluminium salts) [116]. Host endogenous ligands include MSU 
(monosodium urate), calcium pyrophosphate dehydrate, amyloid-β fibrillar peptide and 
ATP. AIM2 has been shown to recognize dsDNA. Phagocytosis of silica crystal and 
fibrous particles of amyloid-β induce lysosomal destabilization and permeabilization which 
leads to the release of cathepsin B into the cytosol. The released cathepsin B then activates 
the NALP3 inflammasome [117, 118]. 
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Figure 8. Type of inflammasomes 
(A) NLRP1 contains, in addition to the NLR-typical LRR and NBD domains, a PYD, a FIIND, and a CARD. 
NLRP1 can recruit pro–caspase-1 and -5 and possibly forms a complex with NOD2. Recruitment of ASC 
enhances activation of pro–caspase-1. (B) NLRC4 contains a CARD that can directly recruit pro–caspase-1. 
(C) NLRP3 activates pro–caspase-1 via recruitment of ASC. (D) AIM2 is a bipartite protein consisting of a 
PYD and DNA-binding. 
Taken from J. Clin. Invest 2009, 119: 3502–3511. 
 
 
 
1.4 Potential role of pattern recognition receptors in autoimmunity 
 
The role of pattern recognition receptors in autoimmunity is well documented. Signaling 
through these receptors may play an important role in the loss of self-tolerance and 
induction of autoimmunity. Several studies reflect the major role for nucleic acid specific 
TLRs in linking innate immunity to adaptive immunity [119, 120]. In one study it was 
reported that TLR 3 and 7 engagement can convert T-cell autoreactivity into autoimmune 
disease, through release of IFNα-mediated upregulation of MHC I on pancreatic tissue 
[121]. TLR7, TLR3, TLR8, and TLR9 all are expressed in the endosomal membrane. 
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Figure 9. Receptor-mediated delivery of autoantigens to TLR7 or TLR9. 
FcγRs are present at the surface of pDCs bind immune complexes and transport both the autoantibody and 
the autoantigen to the cytoplasmic compartment that contains TLR9 (a) or TLR7 (b). The B-cell receptor 
(BCR) at the surface of AM14 B cells (which are specific for IgG2a) has the same function and can 
transport both DNA- and RNA-containing immune complexes (c). BCRs that directly bind autoantigen, 
either DNA (d) or RNA (e), provide the same delivery system. 
Taken from Nat Rev Immunol 2006, 6: 823-35. 
 
 
When self-derived ssRNA is conjugated with RNA-specific antibody, then ssRNA is 
recognized by TLR7, leading to production of IFN-α. Alternatively, ssRNA can engage the 
RNA-specific B cell receptor (BCR) of autoreactive B cells, thereby inducing autoantibody 
production (Figure 9) [122-124]. Both cases might cause autoimmune diseases. This 
concept was supported by TLR7 gene duplication studies [125, 126]. TLR9 is also involved 
in the pathogenesis of autoimmune disorders similar to TLR7 [127]. AM14 B cells express 
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a receptor specific for autologous IgG2a, a specificity that is commonly found in the B-cell 
repertoire of autoimmune-prone mice. This receptor binds monomeric IgG2a with 
relatively low affinity. As a result, in mice that are not prone to autoimmunity, AM14 B 
cells manage to evade the common mechanisms of tolerance induction and develop into 
relatively normal mature B cells. In vitro, AM14 B cells proliferate in response to immune 
complexes that contain IgG2a bound to DNA or DNA-associated proteins and RNA or 
RNA-associated proteins, but these B cells fail to respond to immune complexes of IgG2a 
bound to proteins (Figure 9) [128]. These data established a critical link between the innate 
and adaptive immune systems in the development of systemic autoimmune disease. 
Similarly, pDCs produce IFNα in response to immune complexes containing IgG and 
chromatin. B cell receptor or Fc receptor–mediated internalization of the immune complex 
is thought to result in TLR9-mediated recognition of host derived CpG-DNA within 
chromatin (Figure 9).  
 
IFNα plays a crucial role in the induction of autoimmunity [39]. Activation of APCs by 
TLR9 engagement can break self-tolerance and trigger the development of autoimmunity 
even in a genetically resistant strain such as B10.S mice, transgenic for a T cell receptor 
specific for the encephalitogenic protein peptide, that normally are resistant to spontaneous 
experimental allergic encephalomyelitis (EAE) [129]. Experimental studies with rodents 
suggest that exposure to synthetic CpG-ODN can exacerbate underlying autoimmune tissue 
injury e.g. experimental encephalomyelitis, collagen-induced arthritis or SLE [130, 131]. 
TLR9 activation by CpG–ODN aggravate disease activity in spontaneous immune complex 
glomerulonephritis of MRLlpr/lpr mice [132, 133]. Furthermore, in vertebrates, inhibitory 
DNA sequence elements counterbalance the immunostimulatory effects of unmethylated 
CpG-DNA [134].  
 
 
Certain synthetic ODNs with such inhibitory motifs can block CpG-DNA-induced effects 
[135]. In one study it was reported that inhibiting TLR 7 and 9 using inhibitory 
oligonuclotides ameliorate the disease in MRLlpr/lpr mice [136]. However, experimental 
evidence for a pathogenic role of CpG motifs in self-DNA for lupus is lacking. TLR9-
deficient murine models of SLE showed increased production of anti-DNA autoantibody 
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formation and severe glomerulonephritis and early mortality compare to control mice [137-
139].In vitro studies in autoimmune-prone mice demonstrate that dual signaling via the B-
cell receptor and non-CpG-DNA resulting in synergistic B-cell activation in a TLR9-
independent manner. These results suggest that engagement of a TLR9-independent DNA 
activation pathway may promote autoimmunity, while TLR9 signaling can protect SLE-
like immune pathology in vivo [139]. 
 
TLR-independent nucleic acid recognition receptors might also play a role in the 
pathogenesis of systemic autoimmunity, because activation of these receptors results in 
type1 IFN and other inflammatory cytokine production (Figure 10). As mentioned earlier, 
one form of such induction is mediated by cytosolic RNA sensed by the RIG-1 or MDA5 
helicases. Because most eukaryotic RNA species are known to lack 5′-triphosphate groups, 
which are required for sensing by RIG-1, this feature allows discrimination between self-
RNA and viral RNA. However, RNA transcripts in the nucleus and some RNA species (for 
example, 7SL RNA) in the cytosol of eukaryotic cells display 5′-triphosphates, and 
therefore uptake of apoptotic materials containing such RNA species by conventional DCs 
or macrophages may lead to RIG-1 engagement and type I IFN production [140]. 
Intracellular administration of right-handed B-form dsDNA, the most common 
conformation of mammalian DNA, also triggers TLR-independent production of type I 
IFNs, and such DNA may be present in phagocytosed apoptotic debris. Purified 
nucleosomes have also been found to directly induce MyD88-independent DC maturation 
and production of inflammatory cytokines and chemokines [141]. Inadequate digestion of 
extracellular DNA in DNase I-deficient mice leads to a lupus-like disease [142], and 
function-impairing DNase I gene mutations have been found in a few individuals with 
lupus [143]. In addition, non degraded intracellular DNA in DNAse II-deficient 
macrophages mediates TLR-independent induction of inflammatory cytokines, including 
IFNβ, and causes severe anemia. Induction of type I IFNs and cytokines by uptake of 
mammalian nucleic acids derived from apoptotic materials may amplify immunologic 
responses not only against foreign pathogens, but also against self-antigens in predisposed 
individuals. 
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Figure 10. Endogenous stimuli promoting IFN-α/β production by pDCs and conventional DCs, and 
activation of B cells  
Taken from Nat Med 2007, 13: 543-51 
 
Finally, the role of nucleic acid recognition TLRs in lupus studied in great detail; however 
the role of TLR-independent nucleic acid recognition receptors in lupus not well studied. 
So it is interesting to study disease progression by activating TLR-independent nucleic acid 
receptors with their respective agonists and the role of intracellular TLR-independent 
nucleic acid receptors in lupus pathogenesis. In this study first we tested whether 3P-RNA 
and non-CpG-DNA can aggravate disease or not? 3P-RNA and non-CpG-DNA activate 
RIG-1 and cytosolic DNA pathways respectively. In second study we studied what is the 
impact of these agonists in local kidney cells. For that we stimulated mesangial cells with 
3P-RNA and non-CpG-DNA and analysed signaling pathways and gene expression 
profiles. 
 
1.5 MRLlpr/lprmice- experimental mouse model of lupus nephritis  
 
MRLlpr/lpr mice lack functional expression of the apoptosis-inducing receptor Fas, thereby 
accelerating the manifestation of the autoimmune disease. MRLlpr/lpr mice show systemic 
autoimmunity, massive lymphadenopathy associated with proliferation of aberrant 
CD3+CD4-CD8- T cells and immune complex-derived glomerulonephritis. Starting at 
approximately 3 months of age, levels of circulating immune complexes, such as those 
from spontaneously generated anti-dsDNA antibodies, rise dramatically in MRLlpr/lpr but 
not in wild-type MRL controls. Lymph node weight of MRLlpr/lpr increases 
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approximately 75-fold over controls and renal pathology occurs extensively in MRLlpr/lpr 
at approximately 4 months of age. In MRLlpr/lpr mice, a proliferative glomerulonephritis is 
seen, with mononuclear cell infiltration, endothelial and mesangial cell proliferation, and 
crescent formation [144]. Finally, female MRLlpr/lpr mice die at an average of 17 weeks of 
age and males at 22 weeks.  
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2. Hypothesis/Objectives  
 
Previous studies in our laboratory reported that, administration of TLR ligands in 
MRLlpr/lpr mice can aggravate the disease pathology. These results demonstrated that viral 
infections, which activate TLR signaling, play a significant role in aggravating disease 
pathology. This supports the idea that, viral infections in lupus patients can worsen the 
disease pathology. However, recent findings demonstrated that viral infections also activate 
TLR-independent nucleic acid recognition pathways. These findings prompt us to study the 
TLR-independent nucleic acid recognition pathways in the context of lupus. 
 
1) My first objective was to characterise the effect of exogenous 3P-RNA and non-CpG-
DNA on MRLlpr/lpr mouse model. 
 
2) My second objective was to study the effect of 3P-RNA and non-CpG-DNA-induced 
glomerular inflammation. 
 
3) My third objective was to study whether 3P-RNA and non-CpG-DNA activate 
inflammatory cytokines in mesangial cells and what are the gene expression profiles 
induced by 3P-RNA and non-CpG-DNA. 
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3. Materials and Methods 
3.1 Materials 
 
Equipments  
 
Balances: 
Analytic Balance, BP 110 S  Sartorius, Göttingen, Germany 
Mettler PJ 3000   Mettler-Toledo, Greifensee,Switzerland 
Cell Incubators: 
Type B5060 EC-CO2   Heraeus Sepatech, München, Germany 
Centrifuges: 
Heraeus, Minifuge T   VWR International, Darmstadt, Germany 
Heraeus, Biofuge primo  Kendro Laboratory Products, Hanau, Germany 
Heraeus, Sepatech Biofuge A  Heraeus Sepatech, München, Germany 
ELISA-Reader 
Tecan, GENios Plus   Tecan, Crailsheim, Germany 
Fluorescence Microscope 
Leica DC 300F   Leica Microsystems, Cambridge, UK  
Olympus BX50   Olympus Microscopy, Hamburg, Germany 
LSM510 laser scanning microscope Carl Zeiss, Jena, Germany 
Spectrophotometer 
Beckman DU® 530   Beckman Coulter, Fullerton, CA, USA 
TaqMan Sequence Detection System  
ABI prism ™ 7700 sequence  
detector     PE Biosystems, Weiterstadt, Germany 
Other Equipments 
Cryostat CM 3000   Leica Microsystems, Bensheim, Germany 
Homogenizer T25   IKA GmbH, Staufen, Germany  
Microtome HM 340E   Microm, Heidelberg, Germany 
pH meter WTW    WTW GmbH, Weilheim, Germany 
Thermomixer 5436   Eppendorf, Hamburg, Germany 
Vortex Genie 2™   Bender&Hobein AG, Zurich,  Switzerland 
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Water bath HI 1210   Leica Microsystems, Bensheim, Germany 
 
Chemicals and materials 
Chemicals for the molecular biology techniques 
RNeasy Mini Kit   Qiagen, Hilden, Germany 
RT-PCR primers    PE Biosystems, Weiterstadt, Germany 
dNTP mixture    Amersham Pharmacia Biotech, Freiburg, Germany 
Pre-separation Filters   Miltenyi Biotec, Bergisch Gladbach,Germany 
RNeasy Mini Kit   Qiagen, Hilden, Germany 
DNase solution   Qiagen, Hilden, Germany 
RNeasy Mini Kit   Qiagen, Hilden, Germany 
5 x buffer    Invitrogen, Karlsruhe, Germany 
DTT     Invitrogen, Karlsruhe, Germany 
RNasin    Promega, Mannheim, Germany 
Acrylamide    Ambion Ltd, 36 Cambridgeshire,  
Hexanucleotide   Roche, Mannheim, Germany 
JetPEITM    Polyplus-transfection, IIIkirch, France 
Lipofetamine2000   Invitrogen, Karlsruhe, Germany 
 
Cell culture  
DMEM-medium Biochrom KG, Berlin, Germany 
RPMI-1640 medium             GIBCO/Invitrogen, Paisley, Scotland, UK 
FSC     Biochrom KG, Berlin, Germany 
Dulbecco’s PBS (1×)   PAA Laboratories, Cölbe, Germany 
Trypsine/EDTA (1×)   PAA Laboratories, Cölbe, Germany 
Penicillin/Streptomycin (100×) PAA Laboratories, Cölbe, Germany 
 
Antibodies  
Anti-Mac2    Cederlane, Ontario, Canada 
Anti-CD3    BD Pharmingen, Hamburg, Germany 
Anti-CD4    BD Pharmingen, Hamburg, Germany 
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Anti-CD8    BD Pharmingen, Hamburg, Germany 
Anti-CD25    BD Pharmingen, Hamburg, Germany 
Anti-CD45    BD Pharmingen, Hamburg, Germany 
Anti-7/4    Abd-Serotec, Kidlington, UK 
Anti-Ly6G    BD Pharmingen, Hamburg, Germany 
Anti-mouse IgG1   Caltag Laboratories, Burlingame, CA, USA 
Anti mouse IgG2a   Caltag Laboratories, Burlingame, CA, USA 
Anti-mouse C3 Nordic Immunological Laboratories, Tilburg, 
Netherlands 
Mouse IgG  Rockland Immunochemicals Research, Gilbertsville, 
PA, USA 
FITC-labelled phalloidin  Invivogen, San Diego, USA 
 
Miscellaneous 
Needles     BD Drogheda, Ireland 
Pipette’s tip 1-1000μL                        Eppendorf, Hamburg, Germany 
Plastic histosettes   NeoLab, Heidelberg, Germany 
Preseparation filters   Miltenyi Biotec, Bergish Gladbach, Germany 
Microscope slides   Menzel-Gläser, Braunschweig, Germany 
Silver Impregnation Kit  Bio-Optica, Milano, Italy 
Syringes    Becton Dickinson, Germany 
PVDF membrane    Millipore Immobion, Schwalbach, Germany. 
Hep-2 slides     Biosystems S.A. Costa Brava, Barcelona, Spain 
 
Chemicals  
Acetone Merck, Darmstadt, Germany 
AEC Substrat Packung                      Biogenex, San Ramon, USA 
Diethyl ether Merck, Darmstadt, Germany 
Bovine Serum Albumin                     Roche Diagnostics, Mannheim, Germany 
Cyclophosphamide Sigma-Aldrich Chemicals, Steinheim,Germany 
DEPC                                                 Fluka, Buchs, Switzerland 
 32
DMSO   Merck, Darmstadt, Germany 
EDTA                                                  Calbiochem, SanDiego, USA 
Ethanol  Merck, Darmstadt, Germany 
Formalin Merck, Darmstadt, Germany  
Hydroxyethyl cellulose   Sigma-Aldrich, Steinheim, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Isopropanol                                          Merck, Darmstadt, Germany 
Calcium chloride                                  Merck, Darmstadt, Germany  
Calcium dihydrogen phosphate            Merck, Darmstadt, Germany 
Potassium hydroxide                            Merck, Darmstadt, Germany 
MACS-Puffer Miltenyi Biotec, Bergisch Gladbach, Germany 
Mercaptoethanol                                  Roth, Karlsruhe, Germany 
Sodium acetate                                     Merck, Darmstadt, Germany  
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodium dihydrogen phosphate Merck, Darmstadt, Germany 
Penicillin Sigma, Deisenhofen, Germany 
Roti-Aqua-Phenol Carl Roth GmbH, Karlsruhe, Germany 
SSC (Saline-sodium citrate Puffer) Sigma, Deisenhofen, Germany 
Tissue Freezing Medium  Leica, Nussloch, Germany 
Trypan Blue Sigma, Deisenhofen, Germany 
Oxygenated water DAKO, Hamburg, Germany  
Xylol Merck, Darmstadt, Germany  
ABC reagent      Vector, Burlingame, CA USA 
Histomount      Zymed Laboratories, San Francisco, USA 
DAPI      Vector Laboratories Inc, Burlingame, USA 
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3.2 Methods 
 
3.2.1 Cell culture and stimulation experiments 
 
Cell line 
A murine mesangial cell line (MMC) [145] was maintained under standard culture 
conditions (in an incubator at 37 °C temperature and supplied with 5% CO2) in DMEM 
medium (Dulbecco’s modified Eagle’s medium), supplemented with 2.5% fetal calf serum 
(FCS), penicillin 100 U/ml and streptomycin 100 μg/ml (PS) and described as complete 
DMEM medium. 
 
Isolation of primary mesangial cells 
Kidney cell suspensions were prepared from the cortex (medulla was removed) by mashing 
it in 250 μl of cold complete RPMI medium. The suspension was applied onto 150, 103, 
63, 50 and 45 μm sieves, rinsed with cold PBS, centrifuged (4000 rpm for 7 min), re-
suspended in complete RPMI medium and applied onto 30 μm pre-separation filters. 
Glomeruli remained on the filter. The filter was swapped upside down and rinsed with PBS 
containing 1 mg/ml collagenase IV. Glomeruli were incubated in this solution for 15-20 
min at 37 °C. The cells were then centrifuged and re-suspended and plated in RPMI 
medium supplemented with 20 % FCS, 1 % PS and 1 % ITS (insulin, transferrine, 
selenium). Medium was changed every 4-6 days; the first passage was made after 16-20 
days. 
 
Stimulation experiments 
Mesangial cells were treated with medium control or different concentrations of non CpG-
DNA, 3P-RNA (dose mentioned in results). TLR9 ligand CpG-ODN 1668 and pI:C RNA 
were used as a control in some experiments. All stimulation experiments were done 
without starving conditions (unless mentioned otherwise). After stimulation cell 
supernatants were collected for cytokine measurements and cells were harvested either for 
RNA isolation as described below or for flow-cytometric analysis. 
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3.2.2 RNA isolation, cDNA synthesis and real-time RT-PCR 
 
RNA isolation from cultured cells 
Cells were harvested for RNA isolation after stimulation with different ligands using 
RNeasy Mini Kit, according to the manufacture protocol. Cells were washed with sterile 
PBS to remove residual medium. 350 μl RLT buffer (lysis buffer) containing 10 μg/ml 
beta-mercaptoethanol was added to the cells and scrap the cell with scrapers later lysed the 
cells while pipetting vigorously. Cell lysate was transferred to micro centrifuge tubes and 
frozen at –80 0C until RNA isolation. At the time of RNA isolation the cell lysates were 
thawed, later 350 μl of 70 % ethanol made in 1% diethyl pyrocarbonate treated water 
(DEPC water) was added to it and mixed well. This mixture was transferred to RNeasy 
mini columns held in 2 ml collection tubes and centrifuged at 13000 rpm for 30 seconds. 
The flow-through was discarded and then 350 µl of RW1 buffer added to the column again 
centrifuged at 13000 rpm for 30 seconds. Discard the flow through and treated the column 
with DNase1 solution to prevent DNA contamination in RNA samples. Later on 350 µl 
RW1 buffer was added to the column and centrifuged at 13000 rpm for 30 seconds. 
Discarded the collection tubes and transferred the column in to fresh 2 ml collection tubes. 
500 μl of RPE buffer was added to the column, centrifuged at 1300 rpm for 30 seconds and 
the flow-through was discarded. This step was repeated again. The column was placed in a 
1 ml fresh collection tube, added 35 μl of RNase free water to column and centrifuged 1200 
rpm for 30 sec to collect the RNA. RNA quality was determined by running RNA on 
agarose-formaldehyde gel. 
 
Isolation of RNA from tissues 
When mice were sacrificed on termination of the study, tissues from each mouse were 
preserved in RNA-Later and stored at -20 0C until processed for RNA isolation. RNA 
isolation was carried out using RNeasy Mini Kit. In short tissues (30 mg) preserved in 
RNA-Later were homogenized using a blade homogenizer for 30 seconds at 14500 rpm in 
lysis buffer (600 µl) containing β-mercaptoethanol (10 ul/ml). The homogenate was 
centrifuged at 15000 rpm for 3 min. and 350 µl of supernatant was transferred to fresh 
DEPC (Diethylpyrocarbonate) treated tube. 350 µl of 70 % ethanol was added and the 
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whole mixture was loaded on a RNA column and processed for RNA isolation as 
mentioned. Isolated RNA was stored at -80 0C until further used. 
RNA quality was determined by running RNA on agarose-formaldehyde gel. The RNA 
was quantified by using a UV-Spectrophotometer at 260 nm. 260/280 ratio were also 
measured and values approximately close to 1.6 to 1.9 was considered. 
 
Complementary DNA synthesis and real-time PCR analysis 
The RNA samples were diluted in DEPC water (1 μg/20 μl) and a master mix was 
prepared. The master mix contained, 4.5 μl of 5 x buffer, 0.5μl of 25 mM dNTP mixture, 1 
μl of 0.1 M DTT, 0.5 μl of 40 U/μl RNasin, 0.25 μl of 15 μg/ml acrylamide, 0.25 μl of 
hexanucleotides and 0.5μl of superscript or ddH2O in case of the negative controls. 7 μl of 
this master mix was added to each RNA samples and incubated at 42°C on a thermal 
shaker incubator for 1 hour 30 minutes. Complementary DNA (cDNA) samples were 
collected and stored at -20 0C. For real-time RT-PCR, the cDNA samples were diluted for 
10 times in ddH20. 
 
TaqMan® quantitative real time – PCR 
The real-time RT-PCR was performed on a TaqMan® ABI Prism 7000. The quantitative 
PCR for mRNA is based on the employment of sequence-specific primers and likewise 
sequence-specific probes. The latter are tagged at both ends with a fluorescent molecule. 
The quencher absorbs TAMRA (at the 3'-End) the fluorescence of the other reporter tagged 
material such as FAM or VIC at the 5'-End. The TaqMan® universal PCR master mix 
contained Taq polymerase possessing a 5' -3' polymerase activity and a 5'-3 ' exonuclease 
activity. During the elongation phase of the PCR, specifically bound probe was hydrolyzed 
by the exonuclease and the 5'-tag was set free. With every newly synthesized DNA strand 
fluorescent tag material was set free and the resulting fluorescence was measured at 488 
nm. The resulting fluorescence signal is directly proportional to the quantity of DNA 
synthesized. The CT value (= "Cycle Threshold") was computed for each sample. This is 
the cycle number, of which the reporter fluorescence signal breaks through a user-defined 
threshold. The TaqMan® universal PCR master mix contained the forward and reverse 
primers and the probe was placed on ice. The TaqMan® universal PCR master mix 
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contained PCR buffers, dNTPs and the AmpliTaqGold® as previously mentioned (Taq 
polymerase without 3' to 5' exonuclease activity). 18 μl of the mastermix was pipetted into 
each well of a 96-well plate and 2 μl of template (DNA dilution) was added to each of these 
wells. The plate was sealed and centrifuged at 1000 rpm and analyzed using TaqMan® 
ABI PRISM 7700. For the TaqMan® RT-PCR the following temperature settings were 
used: The first incubation was carried out for 2 minutes at 50 0C followed by 95 0C for 10 
minutes to activate the polymerase. Templates were amplified during 40 cycles each 
comprising 15 seconds incubation at 95 0C followed by 1 minute incubation at 60 0C. The 
RT-PCR for the housekeeping gene 18S rRNA was carried out under similar conditions. 
The CT values were recorded using the ABI PRISM Sequence Detection software (version 
1.0) and the results were evaluated in relation the respective housekeepers. In all cases, 
controls consisting of ddH2O were negative for target and housekeeper genes. For all 
quantitative analyses the cDNA content of each sample was compared with another sample 
following the Ct equation A0/B0 = (1+E)(Ct,B-Ct,A) where A0 is the initial copy number of 
sample A; B0 is the initial copy number of sample B; E, efficiency of amplification; Ct,A, 
threshold cycle of sample A; and Ct,B threshold cycle of sample B. The amplification 
efficiency was defined as 1. All analyses were performed during the same runs including 
control dilution series. Similar amplification efficiencies for targets and housekeeping 
genes were demonstrated by analyzing serial dilutions showing an absolute value of the 
slope of log input cDNA amount versus CT (Ct housekeeping gene - Ct target) of < 0.1. 
 
The Taqman probes used in the study were: 
IL-6: ID Mm00446190_m1 FAM 5’-AAATGAGAAAAGAGTTGTGCAATGG-3’ 
MX1: ID Mm00487796_m1 FAM 5’-TGTACTGCTAAGTCCAAAATTAAAG-3’ 
CCL2: ID Mm00441242_m1 FAM 5’-GCTCAGCCAGATGCAGTTAACGCCC-3’ 
CCL5: ID Mm01302428_m1 FAM 5’-CCAATCTTGCAGTCGTGTTTGTCAC-3’ 
TBX21:ID Mm00450960_m1 FAM 5’-GCAAGGACGGCGAATGTTCCCATTC-3’ 
GATA3:ID Mm00484683_m1 FAM 5’-CCCACCACGGGAGCCAGGTATGCCG-3’ 
FoxP3: ID Mm00475156_m1 FAM 5’-ACCCAGCCACTCCAGCTCCCGGCAA-3’ 
Rorc: ID Mm00441139_m1 FAM 5’-CCCACACCTCACAAATTGAAGTGAT-3’ 
TLR3: ID Mm01207403_ml FAM 5’-CTTTCAAAAACCAGAAGAATCTAAT-3’ 
TLR7: ID Mm00446590_ml FAM 5’-AAAATGGTGTTTTCGATGTGGACAC-3’ 
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Ddx58: ID Mm00554529_m1 FAM 5’-CCAAACCAGAGGCCGAGGAAGAGCA-3’ 
IFIH1: ID Mm00459183_m1 FAM 5’-GACACCAGAGAAAATCCATTTAAAG-3’ 
IFNγ: ID Mm00801778_m1 FAM 5’-CTATTTTAACTCAAGTGGCATAGAT-3’ 
IPS-1: ID Mm00523168_m1 FAM 5’-AGTGACCAGGATCGACTGCGGGCTT-3’ 
TNF: ID Mm00443258_m1 FAM 5’- GTCCCCAAAGGGATGAGAAGTTCCC -3’ 
IL-23: ID Mm00518984_m1 FAM 5’- CAAGGACAACAGCCAGTTCTGCTTG -3’ 
IP10: ID Mm00445235_ml FAM 5’-GACTCAAGGATCCCTCTCGCAAGG-3’ 
DAI: forward primer 5’-CAGGGAAGCACCCCTCTTAT-3’, reverse primer 5’-GAATGAAG 
CTCCTGGGTCAG-3’, core sequence FAM 5’-CCCCCAGAAGTGTCAACCACCACT-3’ 
COX2: forward primer 5’-GGACTGGATTCTATGGTGAAAACTG-3’, reverse primer 5’-GGC 
TTCAGCAGTAATTTGATTCTTG-3’, core sequence FAM 5’-ACTACACCTGAATTTC-3’ 
TGFβ: forward primer 5’-CACAGTACAGCAAGGTCCTTGC-3’, reverse primer 5’-AGTAGA 
CGATGGGCAGTGGCT-3’ (r), core sequence FAM 5’-C GCTTCGGCGTCACCGTGCT-3’ 
IL-2: forward primer 5’-GACTGGTTCTTCTGGTGGAAGCT-3’(f), 5’-TGGGATGCTTGG 
CCATATG-3’ (r), core sequence FAM 5’-TGGGAGTCCAGCCACCAACATTACTTCT -3’ 
 
SYBR green quantitative real time – PCR 
In addition to the use of pre-developed TaqMan assay reagents (PDAR) or primers and 
probe, we also used SYBR green method to analyse the gene expression of interest. SYBR 
green-based detection for real-time PCR only works if only one gene-specific amplicon is 
generated during the reaction. Unlike TaqMan-based assays, SYBR green detection also 
uniquely allows to check the specificity of the PCR using melting. At low temperature, the 
PCR DNA product is double stranded, and it binds fluorescent SYBR green. With 
increasing temperature, the DNA product melts or dissociates becoming single stranded, 
releasing SYBR Green and decreasing the fluorescent signal. Most real-time instruments 
usually plot melting curves as a first derivative. 
Preparation of SYBR green master mixture: 
2x SYBR green master mix  (500 µl Volume) 
10x Taq Buffer without detergent   100 µl 
dNTPs (25 mM)     5 µl 
Rox       20 µl 
PCR Optimizer     200 µl 
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BSA       10 µl 
Sybergreen (stock 1:100 in 20% DMSO)  2 µl 
MgCl2 (25 mM)     120 µl 
H2O                  40.5 µl added to make final volume 50 µl 
 
Preparation of reaction mix for each 20 µl reaction 
2x Sybergreen master mix    10 µl 
Forward primer (10 pmol)    0.6 µl 
Reverse primer (10 pmol)    0.6 µl 
Taq polymerase     0.16 µl 
H2O       6.64 µl 
cDNA (1:10 diluted) 2 µl 
 
The SYBR green forward (f) and reverse (r) oligonucleotide sequences used for the study 
were: 
 
18S rRNA: 5’-GCAATTATTCCCCATGAACG-3’ (f) 
  5’-AGGGCCTCACTAAACCATCC-3’ (r) 
IFIT1:  5’-CAAGGCAGGTTTCTGAGGAG-3’ (f) 
  5’-GACTGGTCACCATCAGCAT-3’ (r) 
OASL2:  5’-TCTGTTGCACGACTGTAGGC-3’ (f) 
  5’-GTGTCCAATCCCTGTTCCC-3’ (r) 
ZC3HAV1: 5’-TTGCAAGCTTAATCTGCTCG-3’ (f) 
  5’-ACCTGGAAGTTCTGTTCCGA-3’ (r) 
IFIH1:  5’-GCCTGGAACGTAGACGACAT-3’ (f) 
  5’-TCATCGAAGCAGCTGACACT-3’ (r) 
MX1:  5’-TCTGAGGAGAGCCAGACGAT-3’ (f) 
  5’-CCAGGTCCTGCTCCACAC-3’ (r) 
IFNβ1:  5’-TCCCTATGGAGATGACGGAG-3’ (f) 
  5’-ACCCATGCTGGAGAAATTG-3’ (r) 
CCL5:  5’-GTGCCCACGTCAAGGAGTAT-3’ (f) 
  5’-CACTTCTTCTCTGGGTTGG-3’ (r) 
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CCL17:  5’-TGCTTCTGGGGACTTTTCTG-3’ (f) 
  5’-ATAGGAATGGCCCC TTTGAA-3’ (r) 
HIF-1α:  5’-CGGCGAGAACGAGAAGAA-3’ (f) 
  5’-AAACTTCAGACTCTTTGCTTC G-3’ (r) 
IL-1β  5’-TTCCTTGTGCAAGTGTCTGAAG-3’ (f) 
  5’-CACTGTCAAAAGGTGGCATTT-3’ (r) 
 
3.2.3 Microarray studies  
Primary mesangial cells (pMC) were stimulated with 0.5 µg of 3P-RNA/CL and 30 µg of 
non-CpG-DNA/CL. Medium/CL-treated cells were used as control. After 6 hours total 
RNA was prepared using RNAeasy Mini Kit. Total RNA (6 µg) from three independent 
preparations in each group were used for biotin-labeled cRNA probe synthesis and 
hybridization of MOE 430Av2 arrays according to the Affymetrix Expression Analysis 
Technical Manual (www.affymetrix.com). Triplicate arrays were scanned and analyzed 
using the Affymetrix GeneChip Operating software (GCOS1.0). Each array was checked 
for general assay quality (3’-5’ ratios for glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) and β-actin <1.1, average background <75 fluorescence units, and scaling factors 
within a two-fold range. The complete data set was deposited into the GEO database 
(http://www.ncbi.nlm.nih.gov/geo; submission #GSE11898). All nine Affymetrix 
Microarray CEL-Files were normalized together using RMA Express version 1.0 beta 2 
(http://rmaexpress.bmbolstad.com). As probe sets definition the default Mouse430_2.cdf 
(included in the library files from the Affymetrix 
http://www.affymetrix.com/support/technical/byproduct.affx?product= moe 430-20) was 
used which defines 45,101 probe sets. Probe data were background-adjusted, quantile-
normalized, and summarized to probe set signals using median polish. Probe set signals 
were logarithmized to base 2. To exclude probe sets in the lower end of the signal range 
which have large signal variation, a background filter cutoff value was defined as the 
maximal signal value obtained from nonhuman Affymetrix-control probe sets multiplied by 
a factor of 1.2 [146]. Probe sets with a signal below cutoff in every array of the 
corresponding comparison as well as Affymetrix control probe sets were excluded from the 
analysis. The cutoff value in controls vs. 3P-RNA/CL was 3.24, and 22,855 probe sets were 
retained; in controls vs. non-CpG-DNA/CL the cutoff value was 3.10, and 24,097 probe 
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sets were retained. Differentially expressed probe sets between controls and 3P-RNA/CL or 
non-CpG-DNA/CL were computed using the Microsoft Excel plugin of SAM, version 1.21 
[147]. Parameters were unpaired tests for significance analysis and 100 permutations for 
false discovery rate estimation. Accepting a false discovery rate of 1%, 4,575 (controls vs. 
3P-RNA/CL) and 7,331 probe sets (controls vs. non-CpG-DNA/CL) were considered 
differentially expressed. Of these, the number of probe sets induced or reduced more than 
1.5-fold were 855 in controls vs. 3P-RNA/CL, and 2,576 in controls vs. non-CpG-
DNA/CL. 
 
3.2.4 RNA silencing studies 
Rig-1 (DDX58) and Dai (Zbp1) genes were knockdown using DDX58 siRNA ON-
TARGETplus SMART pool oligonucleotides and Dai siRNA. Negative control siRNA 
(Ambion/Applied biosystems, Darmstadt, Germany) was used as control. The siRNA 
sequences were as follows: DDX58 (Rig-1), 5’-CAAGAAGAGUACCACUUAAUU-3’, 
5’GUUAGAGGAACACAGAUUAUU-3’, 5’-GUUCGAGAU UCCAGUCAUAUU-3’, 5’-
GAAGAGCACGAGAUAGCAAUU-3’; Dai, 5’-ACAGUCCAGACAGUCCACAU 
CAAAU-3’, 5’-GGCAACAAGAUGACCAUCCACCUUA-3’, 5’-GGAAGACACAG 
GUACAAGCUCUGAA-3’. 1x105 MMC were plated in 12 well plates in antibiotic free 
2% fetal calf serum-DMEM medium. 40nM siRNA was transfected twice with cationic 
lipids (CL) as mentioned above. After 24 hours of second transfection cells were stimulated 
with 1µg of 3P-RNA and 5 µg of non-CpG-DNA for 6 hours. Later on RNA was isolated 
from the cells. To check knock down efficiency realtime- PCR and Western blotting were 
performed for the Rig-1 and Dai. CXCL10 and IL-6 were measure by realtime-PCR and 
ELISA. To check mRNA level and protein level, respectively. 
 
3.2.5 Western blotting 
The following Western blotting protocol was used 
A. Preparation of cell lysates 
1. Collected cells 
2. Lysed the pellet with RIPA lysis buffer on ice for 30 min with rotation 
3. Spin at 14,000 rpm (16,000 g) in an Eppendorf microfuge for 10 min at 4 0C 
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4. Transferred the supernatant to a new tube and discard the pellet. 
5. Determined the protein concentration (Bradford assay from Bio-Rad) 
6. Mixed the protein extract with 6x sample buffer. 
7. Boiled for 5 min at 95 0C 
8. Cool at room temperature for 5 min. 
9. Flash spinned the sample 
B. 10% Polyacrylamide gel was prepared 
 
C. Running the gel 
1. After flash spinning the samples, loaded into the wells. 
2. Ran with constant current (80V for stalking and 120V for resolving). 
 
D. Preparation of membrane 
1. Cut a piece of PVDF membrane. 
2. Wet for about 5 min in methanol on a rocker at room temp. 
3. Removed the methanol and added 1x Blotting buffer until ready to use. 
 
E. Membrane transfer 
1. Kept the membrane on blotting sheet 
2. Take out the SDS-Gel from transfer buffer and keep the gel onto the membrane and 
transfer the protein at 25 Volts for 45 minutes. 
3. When finished, immerse membrane in blocking buffer and block 1hours or 
overnight according to antibody optimal protocol. 
 
F. Antibodies and detection 
1. Incubate with primary antibody diluted in blocking buffer for 60 min at room 
temp/overnight according to antibody. 
2. Wash three times with 0.05% Tween 20 in TBS. 
3. Incubate with secondary antibody diluted in blocking buffer for 45 min at RT 
4. Wash three times with 0.05% Tween 20 in TBS. 
5. Detect with ECL kit and develop the film. 
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3.2.6 Animals and experimental protocol 
Ten week old female MRLlpr/lpr mice were obtained from Harlan Winkelmann (Borchen, 
Germany) and kept in filter top cages under a 12 hour light and dark cycle. Water and 
standard chow (Sniff, Soest, Germany) were available ad libitum. All experimental 
procedures have been approved by the local government authorities. Mice were distributed 
into four groups, each group consisting of 10 to 14 mice. From weeks 16 to 18 of age, 
groups of 12 MRLlpr/lpr mice received intraperitoneal injections every other day with 
either 5% glucose or 20 µg phosphodiester 3P-RNA (5’PPP-
GAAAAGGGGACACACACACACACACACACAC-3’) dissolved in transfection agent in 
vivo-JetPEITM according to the manufactures recommendations. 3P-RNA, devoid of TLR7 
activation, was prepared using in vitro transcription assay kit. A third group of MRLlpr/lpr 
mice was injected with 50 μg phosphodiester non-CpG-dsDNA, (sense 
5’TACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA3’). Non-
CpG-DNA was generated by annealing complementary single strands of DNA [101] and 
dissolved in JetPEI. JetPEI was used to facilitate the uptake of both ligands into the cellular 
cytosol in vivo. As a positive control for the immunostimulatory effects of DNA, a group 
of mice were injected with 40µg of the immunostimulatory A-class phosphothioate CpG-
ODN 1668, 5`-TCG ATG ACG TTC CTG ATG CT-3` dissolved in saline as described 
[132]. Endotoxin levels of all synthetic nucleic acids were negligible as tested by the 
Limulus Assay. Phosphorothioate or phosphodiester backbones of synthetic CpG 
oligonucleotides can modulate their binding affinity to DNA autoantibodies [148]. Neither 
of the aforementioned ODN bound to serum IgG from C57BL/6 mice but all of them bound 
to serum IgG of MRLlpr/lpr mice. Binding affinity was strongest for phosphorothioate 
CpG-DNA particularly at lower concentrations. Binding affinity of phosphodiester non-
CpG-DNA was less potent and was not much affected by complexing non-CpG-DNA to 
JetPEI. At a concentration of 10 μg/ml the binding affinity of all nucleic acid ligands tested 
was almost identical. All mice were sacrificed by cervical dislocation at the end of week 18 
of age. To assess the renal distribution of injected 3P-RNA and non-CpG DNA in vivo 5'-
rhodamine-labeled forms of 3P-RNA/Jet-PEI and non-CpG DNA/Jet-PEI complexes were 
intravenously injected into MRLlpr/lpr mice at 18 weeks of age. Frozen renal sections were 
collected 2 hours later, stained with FITC-labeled phalloidin (1:50) and 4',6-diamidino-2-
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phenylindol (DAPI) and subjected to immunofluorescence imaging. In some experiments 
single dose studies were performed in C57BL/6 mice that were obtained from Charles 
River, Sulzfeld, Germany, or in MyD88-deficient mice that had been backcrossed for 6 
generations to the same background [149]. 
 
3.2.7 Morphological and histological analysis 
The weight ratio of spleen and the bulk of mesenterial lymphnodes to total body weight 
were calculated as markers of the lupus-associated lymphoproliferative syndrome. From all 
the mice, the tissues isolated from kidneys and spleens were placed in plastic histocassettes 
and immediately fixed in 10% buffered formalin (formaldehyde in PBS) for overnight. 
Next day the tissue was processed with an automatic tissue-processor, which processes 
tissues sequentially in 70% ethanol for 5 hours, 96% ethanol for 2 hrs, 100 % ethanol 3.5 
hrs, xylene 2.5 hrs and paraffin for 4 hrs. Histocassettes were taken out from the automatic 
tissue-processor and paraffin blocks were prepared with hot liquid paraffin using a 
Microm- EC 350 machine. These blocks were used for making fine sections for different 
staining (PAS or immuno staining). 5 μm thick paraffin-embedded sections were cut. De-
paraffinization followed by dehydration was carried out by incubating the sections in 
xylene, 100% absolute ethanol, 95%, 80% and 50% ethanol followed by rinsing with PBS 
(2 changes, 3 minutes each). Silver and periodic acid-Schiff stains were done following 
routine protocols. The severity of the renal lesions was graded using the indices for activity 
and chronicity as described for human lupus nephritis [150]. Activity index was considered 
as the sum of individual scores of the following items considered to represent measures of 
adaptive lupus nephritis: glomerular proliferation, leucocyte exudation, 
karyorrhexis/fibrinoid necrosis (X2), cellular crescents (X2), hyaline deposits, and 
interstitial inflammation [150]. The maximum score was 24 points for activity index. 
Chronicity index was considered to be the sum of individual scores of the following items 
considered to represent measures of chronic irreversible lupus nephritis: glomerular 
sclerosis, fibrous crescents, tubular atrophy and interstitial fibrosis. The maximum score 
was 12 points for the chronicity index. 
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For immunostaining all sections were incubated with different primary antibodies either for 
1 hour at room temperature of over night at 4 0C in a wet chamber followed by a wash with 
PBS (2x 5 min). After washing, sections were incubated with biotinylated secondary 
antibodies (1:300, dilution in PBS) and the ABC reagent (Vector, Burlingame, CA USA). 
Slides were washed in phosphate buffered saline between the incubation steps. 
3’3’Diaminobenzidine (DAB) with metal enhancement was used as detection system, 
resulting in a black coloured product. Methylgreen was used as counterstain and slides were 
washed with alcohol (96%) to remove excess stain and xylene. Sections were dried and 
mounted with Vecta Mount. 
 
The following rat and rabbit antibodies were used as primary antibodies: rat anti-Mac2 
(glomerular macrophages, 1:50), rat anti-F4/80 (macrophages, 1:50), anti-Ki-67 (cell 
proliferation, 1:25), anti-CD3 (1:100), anti-mouse Mac-2 (monocytes/macrophages, 1:50), 
anti mouse B220 (early Pro-B to mature B cells, 1:400), anti-mouse IgG1 (1:100), anti 
mouseIgG2a (1:100), anti-mouse C3 (1:20, GAM/C3c/FITC). For each immunostaining 
negative controls staining was perfomed by incubation with a respective isotype antibody 
instead of the primary antibody. For quantitative analysis for evaluation of 
glomerulonephritis glomerular cells were counted using a microscope in 15 cortical 
glomeruli per section. The severity of the renal lesions was graded using the indices for 
activity and chronicity of lupus nephritis (100). Activity index included semi-quantitative 
score of 4 active inflammatory lesions: 1. glomerular leukocyte infiltration, 2. interstitial 
inflammation, 3. glomerular karyorrhexis and. 4. cellular crescents; while chronicity index 
included semi-quantitative score of 3 inflammatory lesions: 1. glomerular sclerosis, 2. 
interstitial fibrosis and 3. tubular atrophy. Semi quantitative scoring of glomerular IgG 
deposits from 0 to 3 was performed on 15 cortical glomerular sections using a 
semiquantitative index as follows: 0 = no signal, 1 = low signal, 2 = moderate signal, and 3 
= strong signal  intensity. Peribronchial and pulmonary inflammation was arbitrarily graded 
from 0 (no inflammation) to 3 (severe inflammation). 
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3.2.8 Evaluation of serum autoantibodies  
Blood and urine samples were collected from each animal at the end of the study period 
from each group of mice. Blood samples were collected under anesthesia by retroorbital 
puncture using capillaries and collected in 1.5 ml micro centrifuge tubes. Serum was 
collected after a settle time of 15 min at room temperature followed by centrifugation of 
blood at 10000 rpm for 5 min. Proteinuria and creatinine were determined using an 
automatic autoanalyzer (Integra 800, Roche Diagnostics, Germany). 
 
Analysis of serum anti-dsDNA autoantibodies by ELISA 
Serum dsDNA autoantibodies were determined by using commercial ELISA kits using the 
following antibodies: anti-mouse IgG1, IgG2a andIgG2b following the manufacturer’s 
protocols. First coat the NUNC maxisorp 96 well flat bottom ELISA plate with 100 μl of 
poly-L-Lysine (Trevigen, Gaithersburg, MD, USA) for 1 hour at room temperature. Later 
on wash the plate with PBS and then incubated the wells with 100 µl of dsDNA (1 μg/ml) 
which was diluted in SSC buffer (1X) for over night at 4 0C. For standards, the wells were 
captured with the capture antibody in coating buffer. Washed the plate and blocking 
soulution was added for one hour, later on standard and samples were added in respective 
wells and incubated for 2 hours. After washing the plate the wells were incubated for 1 
hour with secondary antibody. The plate was developed by adding TMB substrate to the 
wells and incubated for 15 min. The reaction was stopped by adding 1 M H2SO4 and 
absorbance was measured at 450 nm. 
 
Crithidia luciliae assay 
To detect anti-dsDNA more specifically Crithidia luciliae assay was carried out. Diluted 
serum samples (1:100) were applied to fixed C. luciliae slides (Bio Rad Laboratories, 
Munich, Germany) and incubated for 30 min at room temperature. After washing the slides 
with PBS, FITC-labeled goat anti-mouse IgG was used as a detection reagent. Slides were 
mounted with DAPI. C luciliae DNA colocalized with DAPI and the kinetoplast staining 
intensity was quantified from digital images with Adobe Photoshop software. 
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Anti-nuclear antibodies  
Anti-nuclear antibodies (ANA) were determined by incubating serum samples (1:200 in 
PBS) with Hep-2 slides. Fluorescein-labeled goat anti mouse IgG was used as secondary 
antibody (1:50 in PBS). Serum of 6-10 week old C57BL/6 mice was used as negative 
control. The fluorescent patterns of ANA were classified as homogenous nuclear, speckled 
nuclear, cytoplasmic and mitotic patterns [137]. 
 
Anti-Sm and anti Sm-RNP antibodies 
NUNC maxisorp ELISA plates were coated with 1:250 diluted Smith (Sm) antigen 
(Immunovision, Springdale, AR, USA). An anti-Sm IgG (Y12) antibody was used as 
standard. A horseradish peroxidase-conjugated goat anti-mouse IgG (2 mg/ml) was used as 
secondary antibody at a dilution of 1 μl in 50 ml in PBS (pH 7). After that TMB substrate 
was added to develop colour and kept for 20 min in dark. Later on reaction was stopped by 
using 1M H2SO4. Absorbance was measured at 450 nm using spectrophotometer 
(TECAN).The same procedure was followed for anti-SmRNP ELISA. Here the ELISA 
plates were captured with Sm-RNP complex (1000 units/ml) (Immunovision) at a dilution 
of 1:250 instead of Sm antigen. 
 
Rheumatoid factor 
NUNC maxisorp ELISA plates were coated with rabbit IgG at a concentration of 10μg/ml 
(Jackson Immunoresearch, West Grove, PA, USA) overnight at 4 0C. Serum samples were 
diluted 1:100 in PBS (pH 7), 10 week old C57BL/6 mouse serum was used as negative 
control. HRP conjugated goat anti-mouse IgG (2 mg/ml, Rockland Immunochemicals 
Research, Gilbertsville, PA, USA) was used as secondary antibody at a dilution of 1 μl in 
50 ml of PBS (pH7). TMB Substrate was used to develop the colour and reaction was 
stopped by using 2N H2SO4. The absorbance was measured at 450 nm by using 
spectrophotometer. 
 
Cytokines and serum IgG antibodies 
Cytokine levels in sera or cell culture supernatants were determined using commercial 
ELISA kits: IL-6, IL-12p40, CCL2 or CXCL2, IFN-γ (OptEiA, BD, Biosciences, 
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Heidelberg, Germany), IFN-α, IFN-β (PBL Biomedical Labs, NJ), TNFα (BioLegend, San 
Diego, CA) following the protocol provided by the respective manufacturers. The 96-well 
plate was first coated with 100 μl/ well capture antibody (anti-mouse cytokine) at 
recommended dilution and placed overnight at 4 0C. The wells were then aspirated, washed 
with wash buffer and the plate was blocked with assay diluent and incubated at room 
temperature for 1 hour. After washing the plate 100 μl of standard or samples were added 
to the wells and incubated for 2 hours at room temperature. After washing the plate it was 
incubated for one hour with the secondary antibody (avidin-horse raddish peroxidase 
conjugated). This was followed by another wash step. The TMB substrate solution was 
then added to each well at a volume of 100 μl and incubated for 30 minutes. The stop 
solution (2N H2SO4) was then added to each well, and absorbance was measured at 
prescribed wave length (nm), using an automatic plate reader. 
 
For quantification of serum IgG antibodies NUNC maxisorp ELISA plates were coated 
with a capture antibody (anti mouse IgG1 or IgG2a or IgG2b or IgG) in coating buffer. 
Washed the plate and blocking soulution was added for one hour, later on standard and 
samples were added in respective wells and incubated for 2 hours. After washing the plate 
the wells were incubated for 1 hour with secondary antibody. The plate was developed by 
adding TMB substrate to the wells and incubated for 15 min. The reaction was stopped by 
adding 1 M H2SO4 and absorbance was measured at 450 nm. For antibody binding assay 
ELISA plates were coated overnight at 4° C with CpG-DNA, non-CpG-DNA complexed 
with JetPEI and mouse genomic DNA diluted to various concentrations in SSC solution 
1:100 diluted sera from 20 week old MRLlpr/lpr or C57BL/6 mice were added for one 
hour. After washing HRP conjugated anti-mouse IgG was used as secondary antibody. 
Reading was taken at OD 450nm. 
 
3.2.9 Flow cytometry 
Spleens were isolated from the mice of each group after sacrificing mice. Each spleen was 
collected in a sterile petri plate containing the 2-3 ml of ice-cold media (RPMI+ 10 %FCS 
+ 1 % PS) on ice. Cell suspension was prepared by mashing the tissue in to fine fine pieces. 
Cell suspension was passed through 70 μm plastic filter (BD Biosciences) and centrifuged 
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at 1600 rpm at 4°C for 5 min. The supernatant was discarded and the pellet was 
resuspended in to ammonium chloride to lyse red blood cells and incubated for 3 min at 
room temperature. Cells were centrifuged again at 1600 rpm for 5 min. Cells were washed 
twice with PBS and filtered by using 70 μm plastic filters. The cells were resuspended in 
PBS and cell number was counted using Neubauer’s chamber under the microscope. Cells 
were incubated with labelled antibody for 30 min in dark. After washing the cells FACS 
analysis was carried out. The following antibodies were used in this study. Anti-mouse 
CD3, CD4, CD8, CD25, B220 and CD138 antibodies were used to detect CD3+CD4-CD8- 
double negative T cells, CD4+CD25+ regulatory T cells and B220+CD138+ plasma cell 
populations in spleens. CD11c has been stained to identify plasmacytoid and myeloid 
dendritic cells and their activation was assed by costaining for CD40 and MHCII. 
Respective isotype antibodies were used to demonstrate specific staining of cell 
subpopulations. 
 
3.2.10 Other methods 
Proliferation assay 
Proliferation of cells was assessed using CellTiter 96 Proliferation Assay (Promega, 
Mannheim, Germany). The CellTiter 96 Aqueous One Solution contains a novel 
tetrazolium salt compound (MTS) and phenazine ethosulfate that serves as an electron 
coupling reagent. The solution remains stable normally, while the MTS is bioreduced by 
the NADPH or NADH produced by dehydrogenase enzymes in metabolically active cells 
(such as proliferating cells). PMC were grown in 96 well plates for 24 hours before 
stimulation with various doses of 3P-RNA/CL and non-CpG-DNA/CL. After 72 hours 20 
μl CellTiter 96 Aqueous One Solution was added and cells were incubated at 37 0C in 5% 
CO2 for 2 hours and later the optical density (OD) was measured at 492 nm for comparing 
the cell proliferation. 
 
Immunofluorescence microscopy 
Mesangial cells were grown on glass coverslips and then cells were stimulated with 5’-
rhodamine-labeled 3P-RNA and non-CpG-DNA complexed with or without CL. After 2 
hours cells were fixed with 2% paraformaldehyde, 10 mM Pipes, 15% saturated picric acid 
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at pH 6.0. Wash the cells with PBS/glycin and incubated overnight with mouse anti-Rab5 
(BD, Biosciences, Heidelberg, Germany) to mark early endosomes. FITC-labeled goat anti 
mouse IgG was used for detection. MMC cells were scanned using a LSM510 laser 
scanning microscope. 
 
Annexin V-FITC and propidium iodide (PI) assay 
To check apoptosis annexin V-FITC and propidium iodide (PI) assay was performed. Cells 
were stimulated with various concentrations of 3P-RNA/CL or non-CpG-DNA as shown in 
Figure 38 for 24 hours. After stimulation, cells were washed with PBS and resuspended 
them into annexin V binding buffer. Annixin V and PI were added to the cells suspension 
and incubated for 15 min at room temperature in dark. Cells were analyzed by FACS with 
acquisition of 30000 events/sample. 
 
3.2.11 Statistical analysis 
Statistics were done using GraphPad Prism. Data was expressed as mean  SEM (standard 
error of the mean) or mean  standard deviation (SD). Data were analysed using unpaired 
two-tailed t-test for comparison between two groups. One-way ANOVA followed by post-
hoc Bonferroni`s test was used for multiple comparisons. For nonparametric analysis of 
two groups two-tailed Fisher’s exact test and Mann-Whitney U test were performed. 
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4. Results 
 
4.1. Results part- I 
Viral infection can aggravate disease activity of autoimmune diseases SLE but the 
molecular mechanisms remain elusive. Antiviral immune responses might drive 
autoimmune tissue injury via type I interferons, Th1 cytokines or CD8+ T cells as these 
mediators regulate both conditions Antiviral immunity is triggered by conserved viral 
nucleic acid formats via pattern recognition receptors. The role of nucleic acid recognition 
via TLRs in lupus is well studied. We hypothesized that TLR-independent viral nucleic 
acid recognition also aggravates lupus nephritis in experimental MRLlpr/lpr mouse model. 
In this study we used 3P-RNA and non-CpG-DNA as RNA and DNA receptor agonists. 
CpG-DNA was used as a control  
4.1.1. TLR-independent IL-6 induction by 3P-RNA and non-CpG-DNA in vivo 
 
3P-RNA and non-CpG-DNA have been reported to trigger cytokine release via TLR-
independent pathways in cultured dendritic cells [87, 101]. To extend these results in vivo 
serum IL-6 levels were measured before and 6 hours after a single injection of 3P-RNA or 
non-CpG-DNA in to MyD88-deficient and wild-type mice. These results show that MyD88 
was not required to induce IL-6 with either of these two ligands in vivo (Figure 11). 
 
4.1.2. 3P-RNA and non-CpG-DNA dose dependent studies in MRLlpr/lpr mice 
 
To select the compatible dose we did dose studies with 3P-RNA and non-CpG-DNA. 
These studies revealed that a single dose of 20 µg 3P-RNA or 50 µg non-CpG-DNA, but 
not higher doses, potently increased IL-6 or CCL2 serum levels in 16 week old MRLlpr/lpr 
mice (Figure 12). As this response was not dose-dependent we assumed the doses tested to 
be at the plateau-level of the dose response. 
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Figure 11. Serum IL-6 response in MyD88 knocks out mice. C57BL/6 mice with (black bars) or without 
MyD88 (white bars) were injected with a single dose of 3P-RNA, non-CpG-DNA, or CpG-DNA. After 6 
hours serum samples were obtained and IL-6 levels were determined by ELISA. Values are means ± SEM 
from 3 mice in each group, each performed in duplicate. Note that non-CpG-DNA and 3-PRNA injected 
MyD88-deficient mice significantly increase serum IL-6 levels 6 hours after injection as compared to time 
point zero but no response to CpG-DNA ND= not detected. 
 
 
 
 
Figure 12. Dose studies in MRLlpr/lpr mice. Different concentrations of 3P-RNA and non-CpG-DNA 
were injected intraperitoneally into 12 week old MRLlpr/lpr mice as indicated. Serum IL-6 (A) and CCL2 
(B) were measured at 6 hours after injection by ELISA. Data represent means ± SEM from 4 mice in each 
group. Comparison between different doses were analyzed by ANOVA and post-hoc Bonferroni correction, 
* p<0.05. N.d. = not detectable. 
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4.1.3. Non-CpG-DNA induces serum cytokines in MRLlpr/lpr mice 
 
In order to test the effects of transient exposure to 3P-RNA and non-CpG-DNA, 16 week 
old nephritic MRLlpr/lpr mice with preexisting immune complex disease were repeatedly 
injected with 3P-RNA and non-CpG-DNA. Based on above dose studies 16 week old 
MRLlpr/lpr mice were injected with either 5% glucose, 20 µg of 3P-RNA, 50 µg of non-
CpG-DNA or 40 µg CpG-DNA for 2 weeks. Serum cytokine levels were determined 3 
hours after the last injection. Only non-CpG-DNA significantly increased serum TNF and 
IL-12 levels at 18 weeks, although not as high as compared with CpG-DNA (Figure 13). 
By contrast, 3P-RNA and non-CpG-DNA had no effect on levels of IFN-α and IFN-γ, but 
IFN-γ was significantly induced by CpG-DNA (Figure 13). Together, 3P-RNA and non-
CpG-DNA are less potent than CpG-DNA to increase serum levels of TNF, IFN-α, IFN-γ, 
IL-12, IL-6 and TNF in nephritic MRLlpr/lpr mice. 
 
4.1.4. Non-CpG-DNA induces lymphoproliferation and splenomegaly in MRLlpr/lpr 
mice 
Repeated exposure to CpG-DNA can trigger significant lymphoproliferation [151], hence, 
we assessed the weight of spleens and mesenteric lymphnodes at the time of sacrifice in all 
mice. Non-CpG-DNA but not 3P-RNA increased the weight of spleen and mesenteric 
lymphnodes in MRLlpr/lpr mice to the same extent as CpG-DNA (Figure 14A and 14B). 
Thus, non-CpG-DNA but not 3P-RNA induces lymphoproliferation in nephritic 
MRLlpr/lpr mice. 
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Figure 13. Serum cytokine levels in MRLlpr/lpr mice. Serum cytokine levels of 18 week old 
MRLlpr/lpr mice for TNF, IFN-γ, IL-6, IL-12, and IFN-α were measured by ELISA. Data represent 
means ± SEM from 10-12 mice in each group. Comparison between different agonists and vehicle were 
analyzed by ANOVA and post-hoc Bonferroni correction, * p < 0.05 vs vehicle 
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Figure 14. Spleen and lymphnodes in MRLlpr/lpr mice. Weights of spleens (A) and of mesenterial 
lymphnodes (B) were determined in all mice at the end of the study. Comparison between different agonists 
and vehicle were analyzed by ANOVA and post-hoc Bonferroni correction, * p < 0.05 vs. vehicle, ** p < 
0.01 vs. vehicle. 
 
4.1.5. Non-CpG-DNA increased negative T cells and plasma cells in MRLlpr/lpr mice 
 
Non-CpG-DNA increased the percentage of splenic CD4/CD8 double negative T cells and 
B220/CD138 double positive plasma cells in MRLlpr/lpr mice (Figure 15A and 15B). But 
3P-RNA did not affect these two cell population. Interestingly CpG-DNA decreased 
B220/CD138 double positive plasma cell population. 
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Figure 15. Spleen cell subsets in MRLlpr/lpr mice. Spleen cell subsets were determined by flow 
cytometry as follows: (A): CD3+/CD4-/CD8- T cells by staining CD4+ and CD8+ for CD3+ gated T cells; 
the mean percentage of CD3+/CD4-/CD8- T cells from the round marked lower left quadrant were shown 
in right side graph; (B): B220+CD138+ plasma cells, mean percentage of  B220+CD138+ cells from the 
round marked upper right quadrant were shown in right  side graph * p < 0.05 vs. vehicle. Comparison 
between different agonists and vehicle were analyzed by ANOVA and post-hoc Bonferroni correction, * p 
< 0.05 vs. vehicle. 
 
 
 
4.1.6. Dendritic cell activation  
 
We assessed the activation of spleen CD11c+ dendritic cells by flow cytometry for MHC 
class II and CD40 surface expression. 3P-RNA and non-CpG-DNA did not increase surface 
expression of MHC II and CD40 as it was observed with CpG-DNA (Figure 16). 
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Figure 16. Dendritic cells activation in MRLlpr/lpr mice 
Percentage of total splenic CD11c+ dendritic cells expressing MHCII and CD40. Comparison between 
different agonists and vehicle were analyzed by ANOVA and post-hoc Bonferroni correction 
 
 
 
4.1.7. Expression of inflammatory mediators and transcription factors in spleen  
We assessed spleen mRNA expression to check whether the agonist modulate the mRNA 
expression of inflammatory mediators and transcription factors. 3P-RNA but not non-CpG-
DNA induced Mx1, a marker of type I interferon signaling, in spleens of MRLlpr/lpr mice, 
while IFN-γ and TNF mRNA were not induced (Figure 17). Neither 3P-RNA nor non-
CpG-DNA induced IL-6 and CCL2 mRNA as seen with CpG-DNA (Figure 17). The 
mRNA levels of TBX21 and GATA2, respective markers of Th1 or Th2 responses, were 
rather decreased upon 3P-RNA exposure (Figure 17). 3P-RNA and non-CpG-DNA reduced 
IPS-1 mRNA levels (Figure 17). 3P-RNA suppressed Foxp3 mRNA, crucial regulator in 
the development and function of regulatory T cells [152]. This was consistent with reduced 
numbers of CD4/CD25+ T cells in 3P-RNA-treated MRLlpr/lpr mice (Table 4). IL-15 
mRNA levels were not altered any of the three ligands (Figure 17). Thus, 3P-RNA induces 
type I IFN-dependent MX1 signaling and impairs Foxp3-driven regulatory T cells in 
spleens of MRLlpr/lpr mice. 
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Figure 17. Spleen mRNA expression of proinflammatory mediators and transcription factors. Total 
spleen mRNA from 10 mice in each group was used for real-time RT-PCR. The primers for target mRNAs 
used are listed in methods. Data are expressed as means ± SEM of the ratio from the target mRNA per 
respective 18s rRNA expression. Comparison between different agonists and vehicle were analyzed by 
ANOVA and post-hoc Bonferroni correction, * p < 0.05 vs. vehicle, ** p < 0.01 vs. vehicle n = 10 per 
group. 
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  Table 4. Serum autoantibodies and spleen lymphocytes in MRLlpr/lpr mice.  
  
Vehicle 
 
Non –CpG-DNA 
 
3P-RNA 
 
CpG-DNA 
Serum  IgG(mg/ml) 8  ±  1 16 ± 2** 9  ±  1 8  ± 1 
            IgG1(mg/ml) 15.0 ± 2.6 22.0 ± 1.6* 13.0 ± 2.2 14.0 ± 1.5 
            IgG2a(mg/ml) 4.0 ± 0.4 8.9 ± 1.7* 6.0 ± 1.1 6.0 ± 1.3 
            IgG2b(mg/ml) 
2.0 ± 0.2 5.0 ± 0.8* 2.0 ± 0.3 1.0  ±  0.3 
Anti-dsDNA IgG (µg/ml) 144 ± 22 203 ± 37 200 ± 30 206 ± 35 
                     IgG1(µg/ml) 16 ± 6 108 ± 56 104 ± 37 * 85 ± 36 
                   IgG2a (µg/ml) 462 ± 108 671 ± 142 555 ± 105 582 ± 159 
                  IgG2b (µg/ml) 
10 ± 3 43 ± 13* 46 ± 21 60 ± 21* 
Anti-Sm IgG (µg/ml) 6 ± 4 8 ± 3 5 ±  2 4 ± 2 
Rheumatoid factor  
(OD 450 nm) 
0.4 ± 0.1 0.7 ± 0.1 * 0.4 ± 0.1 0.4 ± 0.1 
CD4+ % of cells  in spleen 53.7 ± 0.7 48.2 ± 1.7 53.3 ± 8.4 48.9 ± 1.6 
CD8+ % of cells 16.3 ± 1.1 14.8 ± 1.1 12.9 ± 0.9 17.0 ± 1.3 
CD4+CD25+ % of cells 
2.1 ± 0.2 2.1 ± 0.2 1.4 ± 0.2 1.6 ± 0.1 
 Comparison between different agonists and vehicle were analyzed by ANOVA and post-hoc Bonferroni 
correction * p < 0.05 vs. vehicle. 
 
 
4.1.8. Hypergammaglobulinaemia and DNA autoantibodies in MRLlpr/lpr mice 
 
TLR signaling contributes to B cell activation and the production of selected autoantibodies 
in lupus [153]. Hence, we meticulously analyzed the effects of 3P-RNA and non-CpG-
DNA on serum IgG levels and a number of common lupus autoantibodies. Consistent with 
its effect on spleen plasma cells only non-CpG-DNA significantly increased serum levels 
of total IgG including all isotypes and that of rheumatoid factor (Table 4). Critidiae luciliae 
kinetoplast dsDNA binding was used to detect and quantify anti-dsDNA-IgG. A digital 
quantitative analysis of Critidiae luciliae kinetoplast positivity revealed that both 3P-RNA- 
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and non-CpG-DNA-injected MRLlpr/lpr mice had little but statistically significant higher 
levels of anti-dsDNA-IgG as compared to vehicle controls (Figure 18A). 
 
 
Figure 18. Lupus autoantibodies in MRLlpr/lpr mice. (A) Anti-dsDNA antibodies were assayed by 
binding to Crithidiae luciliae kinetoplast dsDNA and were detected by immunofluorescence. IgG staining 
to C. luciliae dsDNA is shown in green (left), and DAPI staining of DNA is shown in blue (middle). White 
arrows indicate the kinetoplast. Specific anti-dsDNA antibodies are identified by colocalization of IgG and 
DAPI staining in the kinetoplast and appear in mixed colour (right). Specific anti-dsDNA staining of C. 
luciliae kinetoplasts mean intensity was shown in lower panel. Two-tailed Fisher`s exact test was used for 
non-parametric analysis. * p < 0.05 vs vehicle. ** p < 0.01 vs. vehicle (B) Serum antinuclear antibodies 
were detected by Hep2 slide staining as described in methods. Staining patterns were classified as 
homogenous, speckled or cytoplasmic. Data shown on the right lower panel represent the staining pattern 
present in percent of mice of each group as indicated.  
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This was associated with increased homogenous ANA staining pattern on Hep2 cells 
(Figure 18B). Increased anti-dsDNA IgG antibodies were observed with both ligands also 
by ELISA (Table 4). 3P-RNA and non-CpG-DNA had no effect on serum levels of anti-Sm 
IgG (Table 4). Together, transient exposure to 3P-RNA and non-CpG-DNA both 
specifically enhanced the production of dsDNA autoantibodies but not anti-Sm IgG. Only 
non-CpG-DNA increases IgG and rheumatoid factor in sera of MRLlpr/lpr mice. 
 
4.1.9. Renal inflammatory mediator mRNA expression in MRLlpr/lpr mice 
We hypothesized that 3P-RNA and non-CpG-DNA would trigger the expression of 
proinflammatory mediators in kidneys of MRLlpr/lpr mice. 3P-RNA but not non-CpG-
DNA induced IFN-α (Mx1) signaling in the kidney consistent with its effect in spleens of 
MRLlpr/lpr mice (Figure 19A). 3P-RNA but not non-CpG-DNA also induced TNF, IL-6, 
and CCL2 mRNA levels (Figure 19B). CpG-DNA induced a robust induction of TBX21 
consistent with the Th1-like glomerular crescent formation seen in many sections. This was 
neither seen with 3P-RNA nor with non-CpG-DNA (Figure 19C). Also the CpG-DNA-
induced a robust induction of RIG-I and MDA5 was not seen with 3P-RNA or non-CpG-
DNA in kidney (Figure19D). Together, exposure to 3P-RNA and non-CpG-DNA is 
associated with markedly lower changes in the renal expression of inflammatory mediators 
as observed with exposure to CpG-DNA.  
 
4.1.10. Glomerular IgG and complement deposits in MRL lpr/lprmice. 
Higher levels of circulating dsDNA autoantibodies are usually associated with more severe 
immune complex-mediated renal injury. In fact, 3P-RNA and non-CpG-DNA both 
increased glomerular IgG and complement factor C3c staining as compared to control mice 
(Figures 20A and 20B, Table 5). Hence, increased glomerular IgG and C3c deposits were 
rather associated with the consistent effect of 3P-RNA and non-CpG-DNA on dsDNA 
autoantibody production than with hyperglobulinaemia which was selectively induced by 
non-CpG-DNA. 
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Figure 19. Renal mRNA expression of proinflammatory mediators and recognition molecules. Total 
kidney mRNA from 10 mice in each group was used for real-time RT-PCR. The primers for target mRNAs 
used are listed in methods. Data are expressed as means ± SEM of the ratio from the target mRNA per 
respective 18s rRNA expression. * p < 0.05 vs Vehicle. 
 
 
 
 
 
 62
  
Figure 20. Glomerular immune complex deposits in kidneys of MRLlpr/lprmice. (A): Immunostaining 
for total IgG was performed on paraffin-embedded renal sections from of 18 week old MRLlpr/lpr mice of 
all groups. Original magnification x400. (B): Frozen sections of the same kidneys were used for 
immunostaining for complement factor C3 with a FITC labeled antibody (green). Cell nuclei are stained 
with DAPI (blue). Original magnification x400.  
 
 
 
4.1.11. Kidney histopathology 
From the above results one could predict that 3P-RNA and non-CpG-DNA also aggravate 
glomerular pathology, i.e. lupus nephritis, in MRLlpr/lpr mice. Control MRLlpr/lpr mice 
had diffuse proliferative glomerulonephritis with moderate mesangial hypercellularity, 
increase of mesangial matrix, and few periglomerular inflammatory cell infiltrates at week 
18 (Figure 21). 3P-RNA and non-CpG-DNA injections both increased disease activity of 
lupus nephritis as evaluated by the histomorphological activity and chronicity scores for 
lupus nephritis (Figure 21 and Table 5). These effects were less severe and specifically 
were not associated with glomerular crescents or aggravated albuminuria as seen with 
CpG-DNA injections (Table 5). Aggravation of renal pathology was associated with some 
increase in the numbers of glomerular and interstitial macrophages and T cells (Figure 21), 
but again these effects were less prominent as with CpG-DNA. 3P-RNA also increased the 
number of Ki-67 positive proliferating cells in the renal interstitium but not in tubular 
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epithelial cells. Taken together, transient exposure to 3P-RNA and non-CpG-DNA 
aggravates immune complex disease and proliferative lupus nephritis in MRLlpr/lpr mice. 
 
 
 
Figure 21. Histopathology of kidney MRLlpr/lpr mice. Paraffin-embedded lung sections were 
stained with PAS, CD3, Mac-2, and Ki-67 as indicated (original magnification x200-x400). Note that 
3P-RNA, non-CpG-DNA and CpG-DNA treated MRLlpr/lpr mice show higher periglomerular and 
interstitial inflammatory cell infiltrates as compared to vehicle-treated MRLlpr/lpr mice.  
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Table 5. Parameters of lupus nephritis in 18 weeks old MRLlpr/lpr mice. 
  
Vehicle  
 
Non –CpG-DNA 
 
3P-RNA 
 
CpG-DNA 
Proteinuria (mg/mg) 
33 ± 11 37 ± 14 67 ± 39 108 ± 55 
Glom. deposit scores (0-3)     
IgG 
1.2 ± 0.1 1.5 ± 0.1 1.9 ± 0.2 2.1 ± 0.2* 
C3c 0.8 ± 0.1 1.5 ± 0.1* 1.8 ± 0.1* 1.8 ± 0.1* 
     
Histological scores     
Activity index 
6.3 ± 1.5 12.4 ± 2.0 11.0 ± 1.7 15.4 ± 1.7 
Chronicity index 0.6 ± 0.5 2.5 ± 0.9 1.8 ± 0.6 3.6 ± 0.9 
Cellular response  cells/glom. or hpf     
Glom.    Mac2+(cells/glom)      6.9 ± 0.9 8.5 ± 0.8 10.1 ± 0.9 15.3 ± 1.6* 
              CD3+ (cells/glom)    0.7 ± 0.1 1.4 ± 0.2 1.2 ± 0.2 2.2 ± 0.2* 
              Ki67+ (cells/glom)    2.3 ± 0.4 2.5 ± 0.2 2.1 ± 0.2 4.6 ± 0.2* 
     
Interst.    Mac2+ (cells/hpf)      8.0 ± 1.3 10.3 ± 1.0 17.4 ± 3.4 29.3 ± 4.6* 
                CD3+  (cells/hpf)      11.6 ± 1.8 16.0 ± 1.9 17.1 ± 3.0 34.6 ± 4.1* 
                Ki67+  (cells/hpf)      5.8 ± 1.4 6.9 ± 1.2 10.4 ± 1.6 35.3 ± 1.5* 
Tubular  Ki67+   (cells/hpf)      13.9 ± 3.1 12.5 ± 1.7 10.5 ± 1.4 40.2 ± 3.8* 
* p < 0.05 versus vehicle.  
 
4.1.12. Localization of 3P-RNA and non-CpG DNA in mice kidneys  
 
TLR-independent recognition of viral nucleic acids is not restricted to immune cells [85, 
99, 100], Hence, 3P-RNA and non-CpG-DNA might elicit local immunostimulatory effects 
in renal cells and infiltrating immune cells in addition to their systemic effects. To test this 
hypothesis we injected fluorescently labeled 3P-RNA and non-CpG-DNA into 18 weeks 
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old MRLlpr/lpr mice and harvested the kidney for fluorescence microscopy 2 hours later. 
Labeled 3P-RNA and non-CpG-DNA were both found in the kidney and colocalized with 
glomerular cells and tubular epithelial cells in a cytoplasmic staining pattern (Figures 22). 
Obviously, 3P-RNA and non-CpG-DNA localize to the cytosolic compartment of renal 
cells suggesting that they might elicit local effects in addition to their effects on 
autoimmunity. 
 
 
Figure 22. Distribution of 3P-RNA and non-CpG-DNA in kidneys of MRL lpr/lpr mice. Rhodamine-
labeled 3P-RNA and non-CpG-DNA were intravenously injected into 16 week old MRLlpr/lpr mice. Renal 
tissue was harvested two hours later and frozen sections underwent fluorescence microscopy. Rhodamine-
labeled nucleic acids appear in red. FITC phalloidin staining appears in green and DAPI-stained cell nuclei 
are blue. Glomeruli are encircled. Original magnification x200.  
 
 
4.1.13. 3P-RNA and non-CpG-DNA injections induce interferon-related mediators in 
kidney glomeruli of C57BL/6 mice 
Localization experiments showed that 3P-RNA and non-CpG-DNA interacting with 
glomerular cells. However, we do not know whether these ligands could induce cytokine 
production at the glomerular level. MRL lpr/lpr mice are already diseased mice and have 
systemic inflammation. So we injected C57BL/6 mice with either CL (Dotap), 30 µg of 3P-
RNA or 100 µg of non-CpG-DNA in C67BL/6 mice on alternate days for three times. 
Glomeruli were isolated from kidney and mRNA expression profiles were determined by 
real time RT-PCR. 3P-RNA and non-CpG-DNA both induced the glomerular expression of 
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CXCL10/IP10, IFIT1, OASL2, ZC3HAV1, CCL2 and IL-6 (Figure 23). Thus, 3P-RNA 
and non-CpG-DNA injections induce multiple IFN-related mediators and cytokines in 
kidney glomeruli of C57BL/6 mice. 
 
 
Figure 23. 3P-RNA and non-CpG-DNA induced interferon-related mediators in kidney glomeruli. 
C57BL/6 mice were injected 3 times on alternate days with CL, CpG-DNA dissolved in CL or 3P-RNA 
in CL (n=6), and glomerular RNA was isolated 12 hours after the last injection as described in methods. 
Data are means ± SD.* p<0.05 vs. CL. 
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4.1.14. Backbone chemistry of DNA affects their affinity to lupus autoantibodies 
 
Phosphorothioate or phosphodiester backbones of synthetic CpG oligonucleotides were 
shown to modulate their binding affinity to DNA autoantibodies [148], hence, any 
differences the phenotype of non-CpG-DNA- or CpG-DNA-treated MRLlpr/lpr mice may 
be at least partially relate to this effect. We therefore assessed the binding affinities of 
serum IgG from MRLlpr/lpr or C57BL/6 mice to phosphodiester non-CpG-DNA and 
phosphorothioate CpG-DNA, respectively. Neither of the nucleic acids bound to serum IgG 
from C57BL/6 mice but all of them bound to serum IgG of MRLlpr/lpr mice. Binding 
affinity was strongest for phosphorothioate CpG-DNA particularly at lower concentrations 
(Figure 24). Binding affinity of phosphodiester non-CpG-DNA was less potent and was not 
much affected by complexing non-CpG-DNA to JetPEI (Figure 24). The lowest binding 
affinity was noted for mouse genomic DNA. However, at a concentration of 10 μg/ml the 
binding affinity of all nucleic acid formats tested was almost identical. Thus, the backbone 
chemistry of DNA may affect their binding affinity to lupus autoantibodies at certain 
concentrations. 
 
 
Figure 24. DNA autoantibody binding assay. Binding of MRLlpr/lpr and C57BL/6 serum to CpG, 
non-CpG-DNA, non-CpG-DNA complexed with JetPEI and mouse genomic DNA by ELISA. 1:100 
dilutions of sera from MRLlpr/lpr or C57BL/6 mice were tested on CpG (black squares), non-CpG-DNA 
(black diamonds), non CpG-DNA complexed with JetPEI (open triangles) and mouse genomic DNA 
(open circles) coated to polystyrene at concentrations indicated. The solid lines indicate MRLlpr/lpr 
mouse serum while the broken lines indicate sera from C57BL/6 mice. 
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4.2. Results part- II 
  
Interaction of local glomerular cells with immune complexes, that contain viral nucleic 
acids might drive inflammation and further lead to glomerulonephritis. Mesangial cells are 
localized in side glomeruli and play an important role in glomerulonephritis. So we 
hypothesized that 3P-RNA and non-CpG-DNA could directly activate mesangial cells and 
release inflammatory cytokines. Furthermore we analysed gene expression profiles induced 
by 3P-RNA and non-CpG-DNA in mesangial cells. 
 
4.2.1 Characterization of mesangial cells  
Primary mesangial cells (pMC) were prepared from C57BL/6 mice and after five passages, 
immunostaining was performed either with phalloidin or cytokeratin 18 or alpha-smooth 
muscle actin (SMA) to check purity of pMC. pMC were >99% positive for smooth muscle 
actin and >99% were negative for cytokeratin 18 (Figure 25) . 
 
 
Figure 25. Immunostaining of primary mesangial cells.  Immunostaining was performed for pMC either 
with phalloidin or cytokeratin 18 or alpha-smooth muscle actin (SMA). Original magnification x1000.  
 
 
4.2.2. Mesangial cells express nucleic acid-specific pattern recognition molecules 
Primary mesangial cells mRNA expression was determined by the RT-PCR for the nucleic 
acid-specific pattern recognition molecules TLR-3, -7, -8, -9, Rig-1, Mda5, Dai, and Mavs 
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(IPS). Under basal culture conditions pMC expressed Rig-1 and Mavs but not TLR-3, -7, -
8, 9, Dai or Mda5 mRNA (Figure 26). Prestimulation with IFN-β induced TLR3, Dai, Rig-
1, and Mda5 mRNA but suppressed Mavs mRNA expression. 
 
 
Figure 26. IFN-β induces TLR3, Dai, Rig-1, and Mda5 mRNA in primary mesangial cells. Total RNA 
was isolated from pMC after 6 hours exposure to medium or 2000u IFN-β. Real-time RT-PCR data for 
TLR3, TLR7, TLR8, TLR9, Dai, Rig-1, Mda5, and Mavs mRNA are expressed as per respective 18S 
rRNA expression. Data are means ± SD from three experiments each analyzed in duplicates. N.d. = not 
detectable. * p<0.05 vs. medium. 
 
4.2.3. Cationic lipid enhances the uptake of non-CpG-DNA and 3P-RNA in mesangial 
cells. 
In dendritic cells and embryonic fibroblasts 3P-RNA and non-CpG-DNA needs to be 
transfect with CL to reach the intracellular cytosol, for their activation and release of 
cytokines, chemokines or interferons [87, 101]. Consistently, rhodamine-labeled 3P-RNA 
or non-CpG-DNA was hardly detectable in the intracellular cytosol of pMC unless being 
complexed with CL as assessed by confocal microscopy (Figure 27). 
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Figure 27. Cationic lipid enhances the uptake of non-CpG-DNA and 3P-RNA in mesangial cells. 
PMC were exposed to either 1µg of rhodamine-labeled 3P-RNA or 5μg rhodamine-labeled non-CpG-
DNA in the presence or absence of cationic lipid (CL) for 2 hours. Intracellular uptake was detected by 
confocal microscopy and appears as red staining inside of MC. FITC-labeled anti-Rab5 was used to mark 
early endosomes of MC and appears as green staining. Note that the intracellular uptake strongly 
increased when 3P-RNA or non-CpG-DNA were complexed with CL. Images are representative for 3 
independent experiments. Original magnification x400, scale bar = 10 μm. 
 
 
4.2.4. 3P-RNA and non-CpG-DNA activates pMC to produce IL-6 
In the cytosol 3P-RNA and non-CpG-DNA should be able to access their respective 
recognition receptors and activate pMC. In fact, 3P-RNA and non-CpG-DNA both induced 
pMC to produce Il-6 in a dose-dependent manner, only when being complexed with CL 
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(Figure 28A). Pretreatment with either RNase or DNase drastically reduced the release of 
IL-6, which was induced by 3P-RNA and non-CpG-DNA, respectively. This indicates that 
the immunostimulatory effect of these complexes derives from specifically their RNA or 
DNA content only (Figure 28B). 
 
Figure 28. 3P-RNA and non-CpG-DNA induce Il-6 release in mesangial cells. (A): Primary mesangial 
cells were stimulated with increasing doses of 3P-RNA/CL and non-CpG-DNA/CL complexes. The highest 
doses were also tested in the absence of CL (-CL). PolyI: PolyC (pI:C) RNA and CpG oligodeoxynucleotide 
1668 were used as positive and negative controls, respectively. (B): In similar experiments 3P-RNA/CL and 
non-CpG-DNA/CL were preincubated with either RNAse or DNAse. Supernatants were harvested after 24 
hours and analyzed by Il-6 ELISA. Data represent means ± SD. * p<0.05 vs. medium, ** p<0.01 vs. medium. 
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4.2.5. 3P-RNA and non-CpG-DNA activate pMC through TLR-independent pathway 
Most TLRs except TLR3 signal through MyD88 adaptor protein, while TLR3 depends on 
Trif. Consistent with multiple previous studies in other cell types 3P-RNA and non-CpG-
DNA activated pMC via TLR-independent pathways because pMC prepared either from 
MyD88-deficient, Trif-mutant or wild-type mice showed comparable CXCL10, IL-6 and 
CCL5 induction upon 3P-RNA and non-CpG-DNA stimulation (Figure 29). 
 
 
Figure 29 TLR-independent pathway signaling. MyD88-/-, Trif mutant and WT pMC mRNA was isolated 
after 6 hours exposure to 3P-RNA/CL or non-CpG-DNA/CL. Real-time RT-PCR was performed for the 
indicated targets as described in methods. Data are expressed per respective 18S rRNA expression and 
represent means ± SD from three experiments each analyzed in duplicates. 
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4.2.6. Rig-1 mediates 3P-RNA- but not non-CpG-DNA-induced activation of 
mesangial cells 
The recognition of 3P-RNA was reported to involve Rig-1 in dendritic cells [87], hence, 
Rig-1-specific siRNA studies were carried out to confirm the role of Rig-1 for 3P-RNA 
recognition in mesangial cells. Rig-1-specific siRNA significantly suppressed Rig-1 
mRNA levels and protein levels (Figure 30A) and largely prevented IL-6 or CXCL10 
mRNA expression and protein secretion in MC upon exposure to 3P-RNA (Figure 30B and 
C). The 3P-RNA-induced cytokine release was not completely prevented by Rig-1 siRNA 
which may either relate to other contributing signaling pathways or to the technically 
incomplete knock down of Rig-1. By contrast, knock down of Rig-1 did not significantly 
impair the non-CpG-DNA-induced expression of CXCL10 mRNA in MC and had no effect 
on CXCL10 release of MC (Figure 30 D and E). Suppression of Rig-1 somewhat reduced 
the non-CpG DNA-induced expression of IL-6 mRNA at 6 hours but this did not translate 
to the protein level during 24 hours of stimulation (Figure 30 D and E). These data show 
that Rig-1 mediates 3P-RNA but not non-CpG-DNA-induced activation MC cells. 
 
4.2.7 Dai contributes to 3P-RNA but not to non-CpG-DNA induced activation of 
mesangial cells 
 
Dai has been suggested to mediate the recognition of double-stranded B-DNA in in vitro 
[105]. But a recent study reported that mouse embryonic fibroblasts and bone marrow-
derived dendritic cells from Dai knockdown mice showed considerable response to B-DNA 
compared with wild type cells [106]. To test whether Dai is involving in recognition of 3P-
RNA and non-CpG-DNA in MC, Dai-specific siRNA studies were carried out. Dai-specific 
siRNA effectively suppressed Dai mRNA levels in MC (Figure 31A). However, non-CpG-
DNA-induced CXCL10 or IL-6 mRNA expression and protein release was independent of 
Dai (Figure 31B and C). Interestingly, suppression of Dai significantly reduced the 3P-
RNA-induced expression of CXCL10 and IL-6 mRNA and protein release in MC (Figure 
31D and E). Thus, Dai contributes to 3P-RNA but not to non-CpG-DNA-induced 
activation of MC. 
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Figure 30. Rig-1 siRNA studies in mesangial cells. (A): MMC were transfected with Rig-1-specific 
siRNA or non-specific control siRNA and subjected to real-time RT-PCR and Western blotting to 
evaluate the expression of Rig-1. (B) The mRNA expression of CXC10 and IL-6 in siRNA treated MMC 
was measured by real-time RT-PCR after 6 hours treatment with 3P-RNA. (C) CXCL10 and IL-6 protein 
levels were measured by ELISA in siRNA-treated MMC after 24 hours treatment with 3P-RNA. (D) and 
(E) mRNA expression and protein levels of CXCL10 and IL-6 were measured by real-time RT-PCR and 
ELISA, respectively, after treatment with non-CpG-DNA. All RT-PCR data was expressed as per 
respective 18S rRNA expression. Data are means ± SD from three experiments each analyzed in 
duplicate. * p<0.05 Rig-1 siRNA vs. non-specific control RNA. 
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Figure 31. Dai siRNA studies in mesangial cells. (A): MMC were transfected with Dai (Zbp1) specific 
siRNA or non-specific control siRNA and subjected real-time RT-PCR to evaluate the expression of Dai. 
(B): The mRNA expression of CXCL10 and IL-6 in siRNA-treated MMC was measured by real-time 
RT-PCR after 6 hours treatment with non-CpG-DNA. (C) CXCL10 and IL-6 protein levels were 
measured by ELISA in supernatants of siRNA-treated MMC after 24 hours treatment with non-CpG-
DNA. (D) and (E) mRNA expression and protein levels of CXCL10 and IL-6 were measured by real-
time RT-PCR and ELISA, respectively, after treatment with 3P-RNA. All RT-PCR data are expressed as 
per respective 18S rRNA expression. Data are means ± SD from three experiments each analyzed in 
duplicate. * p<0.05 Dai siRNA vs. non-specific control RNA. 
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4.2.8. 3P-RNA and non-CpG-DNA both activate interferon-regulated factor-3 in 
mesangial cells 
 
Innate RNA and DNA recognition receptors can specifically activate a group of 
transcription factors called the interferon regulatory factors (IRF) [154]. To check this 
concept nuclear extracts were isolated from MC after stimulating them with 3P-RNA or 
non-CpG-DNA for 2 hours. 3P-RNA and non-CpG-DNA both increased the 
phosphorylation of IRF3 suggesting that despite different recognition machineries 3P-RNA 
and non-CpG-DNA both share IRF3 as a transcription factor to induce gene expression in 
glomerular MC (Figure 32). 
 
 
Figure 32. IRF3 activation in 3P-RNA- and non-CpG-DNA-stimulated mesangial cells. MMC were 
stimulated with 3P-RNA/ CL and non-CpG-DNA/CL complexes. Nuclear extracts were harvested after 2 
hours and analyzed for phosphorylated Irf3 by ELISA and Western blotting. Data represent means ± SD. * 
p<0.05 vs.CL 
 
 
4.2.9 Unique but overlapping gene-expression program triggered by 3P-RNA and 
non-CpG-DNA in MC 
Shared IRF3 phosphorylation would propose that 3P-RNA and non-CpG-DNA induce 
similar rather than different gene expression patterns in MC. Microarray experiments were 
carried out with Affymetrix mouse genome 430 2.0 array to characterize the pMC mRNA 
expression profiles upon stimulation with complexes of 0.5 μg/ml 3P-RNA/CL and 30 
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μg/ml non-CpG-DNA/CL, two doses that stimulated pMC to secrete comparable levels of 
Il-6 within 24 hours of stimulation (Figure 28A). A large number of genes were found to be 
coinduced by 3P-RNA/CL and non-CpG-DNA/CL (Figure 33), the 30 most coinduced 
genes are listed in table 7. Some genes are specific to either 3P-RNA or non-CpG-DNA 
(Table 6). 
 
 
Figure 33. Microarray analysis comparing the 3P-RNA and non-CpG-DNA induced response pMC 
were stimulated for 6 hr with 3P-RNA or non-CpG-DNA and total RNA was prepared for microarray 
analysis. For all expressed genes, the change relative to untreated cells after 3P-RNA (y axis) or non-
CpG-DNA (x axis) stimulation is plotted in log2 format. Data are from one of three independent 
experiments. 
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Table 6. Genes induced by 3P-RNA and non-CpG-DNA in mesangial cells. 
Gene name   Affymetrix ID    Fold change  Fold change 
non-CpG-DNA 3P-RNA 
 
Ifit1    1450783_at   199  14.5 
Cxcl10    1418930_at   61.7  4.4 
Amphiregulin   1421134_at   52.7  11.6 
Usp18    1418191_at   52.4  2.2 
Isg15    1431591_s_at   34.6  3.2 
Il-6    1450297_at   25.2  14.1 
Ccl5    1418126_at   19.9  4.6 
Epiregulin   1419431_at   14.9  5.3 
Ptgs2    1417263_at   7.0  4.2 
Hmox1   1448239_at   6.8  6.3 
Stanniocalcin 1  1450448_at   5.2  4.1 
Nr4a2    1447863_s_at   5.1  5.2 
Ccl2    1420380_at   4.4  3.0 
Ccl7    1421228_at   4.2  2.7 
Zfp36    1452519_a_at   3.6  1.6 
Poliovirus receptor  1423905_at   3.3  2.0 
Dio2    1418937_at   3.1  7.5 
Mmp13   1417256_at   3.1  3.9 
Csf2    1427429_at   3.4  1.8 
Mcpt8    1449965_at   2.6  1.8 
Hmga2   1450781_at   2.5  1.7 
Il-1rl1    1425145_at   2.5  2.1 
Cd44 antigen   1452483_a_at   2.3  2.1 
Cebpb    1427844_a_at   2.5  2.4 
Ccl17    1419413_at   2.2  1.5 
IFrd1    1416067_at   2.2  1.5 
Bcl6    1421818_at   2.0  1.6 
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4.2.10 3P-RNA and non-CpG-DNA trigger proinflammatory cytokines in mesangial 
cells 
The Affymetrix gene array analysis revealed that the genes strongly coinduced by 3P-
RNA/CL and non-CpG-DNA/CL included IL-6 as well as multiple proinflammatory CC- 
and CXC chemokines, i.e. CXCL10, CCL5, CCL2 and CCL17 (Table6).  
 
 
Figure 34. 3P-RNA and non-CpG-DNA trigger proinflammatory cytokines and chemokines in 
mesangial cells. pMC mRNA was isolated 3, 6, and 9 hours after exposure to 3P-RNA/CL or non-CpG-
DNA/CL. Real-time RT-PCR was performed for the indicated targets as described in methods. Data are 
expressed per respective 18S rRNA expression and represent means ± SD from three experiments each 
analyzed in duplicates. * p<0.05 vs. CL, ** p<0.01 vs. CL.  
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We confirmed the induction of these factors as well as that of COX2/Ptgs2 in pMC at 3, 6 
and 9hours of 3P-RNA/CL or non-CpG-DNA/CL stimulation by real time RT-PCR (Figure 
34). Real-time PCR also revealed that 3P-RNA and non-CpG-DNA induced these genes to 
a more similar extent as suggested by the microarray analysis. We also used real-time RT-
PCR to confirm that 3P-RNA/CL and non-CpG-DNA/CL did not induce Il-1-β, IL-2, TNF-
α, TGF-β, and Hif-1α in pMC as suggested by the Affymetrix gene array. Do these mRNA 
expression data translate to the protein level? 3P-RNA/CL and non-CpG-DNA/CL both 
induced pMC to secrete IL-6, CCL5, and CXCL10 within 24 hours in pMC (Figure 35). 
Together, these data show that 3P-RNA and non-CpG-DNA stimulate MC to produce 
multiple proinflammatory cytokines and chemokines. 
 
 
Figure. 35. 3P-RNA and non-CpG DNA trigger CCL5 and CXCL10 mesangial cells. Cell supernatants 
were harvested from MC after 24 hours of stimulation 3P-RNA and non-CpG-DNA and analyzed by 
ELISA for Ccl5 and Cxcl10. Data are means ± SD from three experiments each analyzed in duplicates.* 
p<0.05 vs. medium. 
 
 
4.2.11 3P-RNA and non-CpG-DNA trigger type I interferon and interferon-related 
mediators in mesangial cells 
The gene array analysis suggested that many of the genes induced by both 3P-RNA/CL and 
non-CpG-DNA/CL relate to the type I IFN signaling cascade (Table 6). Real-time RT-PCR 
was used to confirm the induction for several of these antiviral molecules at 3, 6, and 9 
hours of stimulation in pMC. For example, the translation regulator IFN-induced protein 
with tetratricopeptide repeats (IFIT)-1, the nuclear GTPase myxovirus resistance (MX)-1, 
and the nuclear RNAseL activator 2’,5’-oligoadenylate synthetase-like 2 (OASL2) were all 
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induced like IFN-β mRNA (Figure 36). Later the production of IFN-α and IFN-β were 
confirmed by ELISA in pMC supernatants 24 hours after stimulation with 3P-RNA/CL or 
non-CpG-DNA/CL (Figure 37). Together, these data show that 3P-RNA and non-CpG-
DNA stimulate MC to produce IFN-α and IFN-β as well as other IFN-induced genes like 
MX-1, OASL2, and IFIT1 proteins. 
 
Figure 36. 3P-RNA and non-CpG-DNA trigger IFN-related genes in mesangial cells. Primary MC 
mRNA was isolated 3, 6, and 9 hours after exposure to 3P-RNA/CL or non-CpG-DNA/CL. Real-time RT-
PCR was performed for the indicated targets as described in methods. Data are expressed per respective 
18S rRNA expression and represent means ± SD from three experiments each analyzed in duplicates. * 
p<0.05 vs. CL, ** p<0.01 vs. CL.  
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Figure 37. 3P-RNA and non-CpG-DNA trigger IFN-related genes in mesangial cells: Cell supernatants 
were harvested from MC after 24 hours of stimulation 3P-RNA and non-CpG-DNA and analyzed by ELISA 
for IFN-α and IFN-β. In similar experiments performed in the presence or absence of RNase or DNase. Data 
are means ± SD from three experiments each analyzed in duplicates.* p<0.05 vs+. medium. N.d. = not 
detected. 
 
 
 
 
4.2.12 3P-RNA and non-CpG-DNA both trigger apoptosis in mesangial cells 
Viral recognition commonly triggers apoptotic cell death which is thought to contribute to 
the control of viral replication and spreading. The gene array analysis suggested that many 
of the genes induced by both 3P-RNA/CL and non-CpG-DNA/CL relate to cell cycle 
regulation (Table 5). We therefore analyzed the impact of 3P-RNA/CL and non-CpG-
DNA/CL on pMC proliferation. At lower concentrations 3P-RNA/CL and non-CpG-
DNA/CL increased the number of pMC cells over a period of 72 hours (Figure 38A). At 
higher concentrations the number of pMC declined with both nucleic acids in a dose-
dependent manner (Figure 38A). Flow cytometry revealed that 3P-RNA/CL and non-CpG-
DNA/CL stimulation mainly increased the numbers of propidium iodine and annexin-V 
double positive MC indicating late apoptotic MC (Figure 38 B and C). Thus, in addition to 
cytokine and chemokine release and type I IFN signaling 3P-RNA and non-CpG-DNA 
trigger MC apoptosis, especially at higher concentrations. 
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Figure 38. 3P-RNA and non-CpG-DNA trigger apoptosis in mesangial cells. (A) pMC cells were 
stimulated with increasing doses of 3P-RNA/CL or non-CpG-DNA/CL as indicated. poly I:C RNA 
(pI:C) 50 μg and fetal calf serum 30%(FCS) were used as controls. After 72 hours the number of 
proliferating cells was determined by a proliferation assay as described in methods. (B) In similar 
experiments stimulated MC were stained with propidium iodine (PI) and anti-annexin-V for 24 hours. 
Flow cytometry analyzed annexin-V/PI double positive cells (encircled). (C): Quantitative analysis of the 
flow cytometry data shows the percentage either annexin-V/PI double positive cells as means ± SD. * 
p<0.05 vs. CL. 
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5. Discussion 
 
Viral infection can aggravate disease activity of autoimmune diseases like SLE but the 
molecular mechanisms remain unclear. The innate immune system involved in detecting 
viral ligands through TLRs. Several studies showed that a transient exposure to viral 
nucleic acids can trigger disease activity in SLE via TLR-dependent pathways [132, 155-
157]. The recent discovery of TLR-independent viral nucleic acid recognition raised 
questions about the role of TLR-independent viral nucleic acid recognition in 
autoimmunity. In this study we used the model of spontaneous SLE-like autoimmunity in 
MRLlpr/lpr mice to study the effects of intermittent exposure to 3P-RNA and non-CpG-
DNA, synthetic ligands to Rig-1 and recently identified cytosolic dsDNA receptor Dai and 
AIM2 or yet unknown cytosolic dsDNA receptors, in vivo [87, 88, 99, 101, 105]. 3P-RNA 
and non-CpG-DNA were reported to elicit immune responses via TLR-independent 
mechanism. Here we provide first evidence that 3P-RNA and non-CpG-DNA can 
aggravate both autoimmunity and autoimmune tissue injury in nephritic MRLlpr/lpr mice 
and that these ligands exacerbate disease through different types of immune responses. 
 
Antiviral host defense requires an activation of innate immunity including the local 
production of type I interferons. Previous reports showed that a transient exposure to viral 
dsRNA or imiquimod both aggravates lupus nephritis in MRLlpr/lpr mice in association 
with enhanced IFN-α signaling and proinflammatory cytokines [155, 156]. While 
imiquimod triggers endosomal TLR7 signaling via MyD88/IRF-7 [69], viral dsRNA can 
signal either via endosomal TLR3/TRIF/IRF-3 or by activating both cytosolic RIG-like 
helicases [158]. 3P-RNA specifically interacts with Rig-1 [87, 88]. In this study we used 
the immunostimulatory ssRNA triphosphate oligonucleotide to mimic viral 3P-RNA, 
because its 19 bases were identified to be the minimal length to efficiently induce IFN-α 
via Rig-1 in monocytes [87]. Repeated injections with 3P-RNA enhanced MX1 mRNA 
expression in spleens and kidneys of MRLlpr/lpr mice indicating a type I interferon 
signature but an increase in IFN-α in serum level was not found. This is in line with the 
observation that autoimmunity in MRLlpr/lpr mice depends on IFN-γ rather than on type I 
IFNs as compared to autoimmune NZB/NZW mice [159]. In the spleen IFN-α is mainly 
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produced by plasmacytoid dendritic cells in a TLR-dependent manner [102] but 3P-RNA 
can activate Rig-1-dependent type I IFN production and also in non-immune cells [85, 99]. 
Injected 3P-RNA localized to glomerular cells and tubular epithelial cells in kidneys of 
MRLlpr/lpr mice like cytosolic staining pattern and exposure of 3P-RNA and non-CpG-
DNA to C57/BL6 mice induced inflammatory cytokine production in kidney glomeruli. 
Consistently, Rig-1 expression was reported to localize to mesangial cells in human lupus 
nephritis [160]. Kidneys of 3P-RNA-injected mice expressed increased levels of CCL2 
which was consistent with the moderate increase in glomerular and interstitial macrophage 
and T cell infiltrates, because the CC-chemokine CCL2 mediates recruitment of these cells 
to the glomerular and interstitial compartment in MRLlpr/lpr mice [161]. Moreover 
kidneys of 3P-RNA-injected mice expressed increased levels of IL-6 and TNFα. Both 
cytokines play a role in the regulation of immune cells, inflammation and apoptosis; further 
can lead to tissue damage. 3P-RNA also induced the production of dsDNA autoantibodies 
and subsequent glomerular IgG and complement deposits although 3P-RNA did not trigger 
plasma cell expansion and hypergammaglobulinaemia. Whether the discrepancy between 
3P-RNA-induced autoantibody production and lack of plasma cell proliferation relates to 
the suppressive effect of 3P-RNA on Foxp3 mRNA expression and the numbers of spleen 
CD4CD25+ T cells or to another yet undefined mechanism remains to be determined. 
Thus, 3P-RNA aggravates lupus nephritis by enhancing systemic autoimmunity and by 
aggravating local inflammation. 3P-RNA induces IFN-α signaling, dsDNA autoantibody 
production and aggravates immune complex disease, renal CCL2 expression, and immune 
cell infiltrates. 
 
Viral DNA can be recognized by TLR9 and activate immune cells. TLR9 recognizes 
unmethylated CpG motifs. Recently, it was reported that DNA can initiate immune 
responses through TLR9-independent pathways in a sequence-independent manner [101]. 
TLR9-dependent recognition of CpG-DNA causes B cell proliferation and activation of 
dendritic cells. Repeated injections with CpG-DNA caused significant lymphoproliferation 
and lymphofollicle destruction in mice [151, 162]. In MRLlpr/lpr mice a transient exposure 
to CpG-DNA increases the production of DNA autoantibodies and fosters crescentic 
glomerulonephritis [132]. The role of TLR9 in SLE is still unclear because TLR9 does not 
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protect from spontaneous anti-DNA autoantibody formation and glomerulonephritis. 
Furthermore disease induction is aggravated and additional nucleolar antibody specificity 
develops in autoimmune TLR9-deficient mice. MRLlpr/lpr mice lacking TLR9 developed 
more severe clinical disease and showed early mortality [137, 139]. Hence, other pathways 
might be responsible for DNA autoantibody production. DNA autoantibodies are the 
hallmarks of lupus. In the present study repeated injections of 45 bases long, double-
stranded, phosphodiester non-CpG-DNA induced plasma cell expansion, 
lymphoproliferation, splenomegaly, and dsDNA autoantibodies in MRLlpr/lpr mice similar 
to CpG-DNA. Stetson and Medzhitov have described overlapping but unique gene 
expression programs were elicited by CpG- and non-CpG DNA in dendritic cells, e.g. in 
terms of IL-12 induction [101]. Consistent with these data, CpG-DNA strongly induced 
serum IL-12, IL-6 and TNF levels. Moreover CpG-DNA reduced spleen GATA3 mRNA 
expression in MRLlpr/lpr mice but this was not observed in non-CpG-DNA-injected 
MRLlpr/lpr mice. IL-12 production has been implicated with crescent glomerular lesions in 
murine glomerulonephritis. In fact, non-CpG-DNA did not induce crescentic 
glomerulonephritis and did not induce IL-6 and CCL2 mRNA in kidneys as did CpG-DNA. 
This may explain why non-CpG-DNA was less potent in aggravating lupus nephritis as 
compared to CpG-DNA. CpG-DNA activated more production of cytokines in comparison 
to non-CpG-DNA. However; non-CpG-DNA induced hypergammaglobulinaemia, 
rheumatoid factors, and dsDNA autoantibodies and this was associated with increased 
glomerular IgG, C3c deposits and glomerular pathology. MyD88-dependent recognition of 
CpG-DNA and MyD88-independent recognition of non-CpG-DNA share the potential to 
trigger B cell activation in vivo, however we observed decrease number of B220+CD138 
cells with CpG injection, may be this is due lymphofollicle destruction[151]. CpG-DNA 
and dsDNA differ in terms of shifting T cell function to the Th1-type, which is associated 
with crescent formation in mice. After intravenous injection with rhodamine-labeled non-
CpG-DNA reached kidney glomerular cells. Exposure of non-CpG-DNA to C57/BL6 mice 
induced inflammatory cytokine in kidney glomeruli. These experiment results and 
localization experiment results strongly provide evidence that non-CpG-DNA and 3P-RNA 
can reach to the glomerular compartment and induce local inflammation. 
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Table 7. PAMPs and their effects on SLE pathology 
 Lipo-
peptide 
TLR-2 
LPS 
 
TLR-4 
dsRNA 
 
TLR-3 
ssRNA 
 
TLR-7 
CpG-DNA 
 
TLR-9 
dsDNA 
DAI and 
others 
3P-RNA 
 
RIG-1 
Lypmpho-
proliferation 
    -    +    -    +  +++  +++    - 
Regulatory 
T-Cells 
    ?    ?    ?    ?    ?    ?    + 
dsDNA- 
antibodies 
    +    +    -    +  +++  +++    + 
Glomerular 
IG 
    +    +    -    +  +++    +    + 
Mesangio-
lysis 
    -    -  ++    -    -    -    - 
Protenuria  +++    +   +    +    +    +    + 
Inflammation   ++   ++  ++   ++   ++    +    + 
 
 
Altogether the immune responses triggered by 3P-RNA and non-CpG-DNA differently 
modulate autoimmunity but both aggravate autoimmune tissue injury such as lupus-like 
nephritis in MRLlpr/lpr mice. These data extend the previous finding that TLR-
independent recognition of RNA and DNA initiate overlapping but still different gene 
expression patterns. Even though 3P-RNA and non-CpG-DNA induced similar gene 
expression in mesangial cells but in vivo both ligands aggravated the disease in a different 
fashion. RNA and DNA both enhanced the production of dsDNA autoantibodies, the 
glomerular deposition of IgG and subsequent complement activation in the glomerulus. 
However, the immunostimulatory effects of 3P-RNA and non-CpG-DNA differ in terms of 
type I IFN signaling, Foxp3-mediated regulatory T cells and plasma cell proliferation in 
MRLlpr/lpr mice. These data suggest that viral 3P-RNA and dsDNA differently modulate 
autoimmunity but still both aggravate autoimmune tissue injury, e.g. by activating non-
immune cells at the tissue level. These data added 3P-RNA and non-CpG-DNA in to 
pathogen-associated molecules that can aggravate lupus disease (see Table 7). These 
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pathogen-associated molecules modulate disease progression in different ways (Table 7). 
Finally, these data support the hypothesis that cytosolic nucleic acid receptors might play a 
role in autoimmunity. 
 
Viral infections exacerbate disease activity of preexisting glomerular diseases like IgA 
nephropathy, lupus nephritis or renal vasculitis [163]. Viral infections can induce de novo 
immune complex glomerulonephritis, e.g. hepatitis C virus-associated glomerulonephritis. 
Mesangial cells occupy a central position in the glomerulus. The glomerular sieving 
process exposes MC to all types of circulating micro- and macromolecules including viral 
particles during extrarenal viral infections. Viral nucleic acids remain partially protected 
from nuclease digestion when being complexed to immunoglobulins, nucleoproteins or 
lipid particles, a process that also supports the uptake of such particles into intracellular 
compartments [123, 164, 165]. Hence, glomerular immune complex deposits are usually 
taken up and processed by glomerular mesangial cells [166]. Viral nucleic acids activate 
mesangial cells. It was reported that viral dsRNA activates human and murine MC to 
produce IL-6 and CCL2 in vitro and in vivo which is attributed to TLR3, because the only 
nucleic acid-specific TLR expressed by mesangial cells [155, 167] (mesangial cells won’t 
express TLR7 and 9). TLR3 recognizes dsRNA, but viral nucleic acids occur in formats 
other than dsRNA, like the 5`-triphosphate RNA, ssRNA, homopolymeric ribonucleotide 
motifs of hepatitis C virus RNA [89] and various DNA formats. In vivo studies on 
MRLlpr/lpr mice were shown that 3P-RNA and non-CpG-DNA can reach to the 
glomerular compartment and induce local inflammation. We also demonstrate that 3P-RNA 
and unmethylated non-CpG-DNA are potent activators of mesangial cells. Consistent with 
the published literature we confirmed that 3P-RNA and non-CpG-DNA activate mesangial 
cells via TLR-independent recognition pathways [140]. Both MyD88-deficient and Trif 
deficient pMC produced CXCL10, IL-6 and CCL5 similar like wild type pMC. 3P-RNA 
and non-CpG-DNA both induced IL-6 production in dose-dependent manner. RT-PCR data 
demonstrated that mesangial cells express Rig-1, Mda5 and Dai. Rig-1 and Dai were shown 
to be involved in the recognition of 3P-RNA and viral non-CpG-DNA, respectively [87, 
88, 101]. The role of Rig-1 for the recognition of 3P-RNA has been confirmed with Rig-1-
deficient mice by several groups[87, 88]. Consistent with published results, Rig-1 knock 
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down in mesangial cells significantly reduced 3P-RNA induced CXCL10 and IL-6 
expression at mRNA level and protein level. The role of Dai for the recognition of 
unmethylated dsB-DNA is unclear because cells derived from Dai-deficient mice respond 
to B-DNA o a similar extent to cells derived from wildtype mice [106]. In a follow up 
study Wang, et al. admitted that other cytosolic DNA sensors must exist [168]. The data 
from Dai knockdown experiments demonstrate that Dai (as well as Rig-1) are dispensable 
for non-CpG-DNA recognition in MC. Still, the recognition of non-CpG-DNA seems to 
take place inside MC as complex formation with CL was required for dsDNA-induced MC 
activation. Surprisingly, transfection with Dai-specific siRNA reduced IL-6 and CXCL10 
the mRNA expression in MC stimulated with 3P-RNA. The significance of this finding 
remains doubtful because ELISA-based quantification of the respective proteins in MC 
supernatants showed significant but only little reduction with the Dai knock down. So far 
studies have not addressed a potential role of Dai in 3P-RNA-induced cell activation. 
Recent studies reported a role of Rig-1 in the recognition of dsDNA, however, this 
mechanisms seems to be species specific and dsDNA format-specific [102, 113]. It appears 
that the role of cytosolic RNA- or DNA-binding proteins for innate pathogen recognition 
varies between different cell types, and different species. Immunofluorescence data showed 
that rhodamine-labeled 3P-RNA and non-CpG-DNA both reach the cytoplasm when they 
have complexed with cationic lipids. So cytoplasmic translocation is important for these 
ligands to activate cells. 3P-RNA and dsDNA both activate IFNs although 3P-RNA and 
dsDNA recognition in MC involves different pathways. Both activate the transcription 
factor IRF3 [101]. This may explain why 3P-RNA and non-CpG-DNA induce almost 
identical gene expression programs in MC. Transcriptome analysis revealed that 3P-RNA 
and non-CpG-DNA predominantly induce the expression of four types of genes, i.e. 
proinflammatory cytokines (IL-6, IFN-α, IFN-β), chemokines (CCL2, CCL5, CCL7, 
CCL17, CXCL10), a type I IFN-related gene signature (IFIT1, MX1, OASL2, IFNβ 1, 
IFIH1, and ZC3HAV1), and cell growth-related genes. The local expression of cytokines 
and chemokines is important for antiviral defense as they create a local inflammatory 
environment and promote the recruitment of antigen-presenting cells and immune effector 
cells. Among the proinflammatory chemokines CXCL10 is of particular interest because it 
is specifically induced by IFN and preferentially recruits cytotoxic T cells via the 
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chemokine receptor CXCR3 [169]. Type I IFNs have multiple other immunoregulatory 
functions and specifically trigger antiviral effectors. For example, mesangial cells 
expressed the nuclear GTPase Mx1 that can bind to viral nucleocapsids or other viral 
components and degrades them [170]. Mesangial cells also induced OASL2 that activates 
the antiviral endoribonuclease RNAse L, a mechanism that initiates the cleavage of viral 
RNA and that can produce small self-RNA cleavage products which enhance type I 
signaling via Rig-1, Mda5, and Mavs in a positive amplification loop [170]. This study 
documented for the first time type I IFN release in mesangial cells. Non-CpG-DNA 
induced cell proliferation significantly at low concentrations; on the other hand 3P-RNA 
did not induce cell proliferation. This is may be due to some cell cycle and proliferation 
related genes which were induced specifically by non-CpG-DNA in arrays. We have 
addressed this topic in subsequent studies while these results are not mentioned here. Viral 
infection leads to cell death; to prevent viral replication and spreading. Consistent with 
these phenomena 3P-RNA and high concentration of non-CpG-DNA induced MC 
apoptosis. Microarray data showed that 3P-RNA- and non-CpG-DNA induced large 
number of antiviral genes in mesangial cells. However, the response spectrum remains 
limited compared to that of professional antigen-presenting cells. In antigen-presenting 
cells the recognition of viral RNA and DNA also reduces antigen uptake and fosters cell 
maturation, antigen-presentation as well as costimulation. Non-immune cells like 
Mesangial cells lack many of these functions because they are functionally and structurally 
differentiated to serve specialized functions in glomerular microenvironment. Mesangial 
cells are considered to represent specialized perivascular pericytes that maintain the 
structure of the glomerular capillary loop, control glomerular hemodynamics and clear 
macromolecules that cannot pass the glomerular filter membrane [171]. These data suggest 
a novel and previously unrecognized function of MC to trigger specific antiviral immune 
responses upon immune recognition of viral 3P-RNA and non-CpG-DNA. These data 
implicate a novel mechanism for the pathogenesis of viral infection-associated 
glomerulonephritis. These results were supported the in vivo experiments that 3P-RNA and 
non-CpG-DNA induced antiviral genes in glomeruli of C57BL/6 mice. In these 
experiments the mRNA expression may also originate from other glomerular cells than 
MC. In fact, podocytes and glomerular endothelial cells have a similar capacity as MC to 
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trigger antiviral genes upon immune recognition of viral RNA and DNA [172]. Direct viral 
infection and replication in glomerular cells has rarely been documented [173]. However, 
de novo glomerulonephritis or flares of preexisting chronic glomerulonephritis are common 
during extrarenal viral infections. The activation of antiviral immune responses in 
glomerular cells, as described here, will always be unable to control the extrarenal viral 
infection but can induce or aggravate glomerular pathology.  
 
Together the data unravels TLR-independent RNA and DNA recognition in mesangial cells 
and showed that other formats of nucleic acids can activate these cells Dai is dispensable 
for non-CpG-DNA recognition. Rig-1 and Dai are both involved in the recognition of 3P-
RNA in glomerular mesangial cells. These data suggest that the role of Rig-1 and Dai for 
innate pathogen recognition can vary between cell types and species. However, complexed 
3P-RNA and dsDNA trigger a common antiviral response program in MC and in the 
intrarenal glomerular compartment which may explain how extrarenal viral infections can 
trigger glomerulonephritis. These data support the idea that immune complexes that are 
associated with nucleic acids can activate glomerular cells, which leads to glomerular 
inflammation. These data open a new field, i.e. the function of antiviral mechanisms in 
glomerular cells which was neglected in the past. These mechanism seems to represent 
another example how functionally inappropriate immune responses trigger immunity-
related kidney damage. 
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6. Summary  
 
Non-CpG-DNA and 3P-RNA activated mesangial cells to produce inflammatory cytokines 
and type 1 interferons in TLR-independent manner. Both ligands induced similar gene 
expression patterns in mesangial cells. This data unravelled the existence of TLR-
independent pathways and production of type1 interferons in mesangial cells. These results 
substantiate the idea that, immune complexes that are associated with nucleic acids can 
activate glomerular cells via TLR-independent manner, which leads to glomerular 
inflammation. Furthermore, exposure of non-CpG-DNA and 3P-RNA in MRLlpr/lpr mice 
aggravated the disease pathology in different manner. Even though 3P-RNA and non-CpG-
DNA induced similar gene expression in mesangial cells but in vivo both ligands 
aggravated the disease in different fashion. 3P-RNA induced type I IFN signaling and 
decreased the number of regulatory T cells while non-CpG-DNA induced plasma cell 
expansion, lymphoproliferation and splenomegaly. However, both ligands induced the 
production of dsDNA autoantibodies and increased the glomerular deposition of IgG. 
These data suggest that viral 3P-RNA and non-CpG-DNA differently modulate 
autoimmunity but still both aggravate autoimmune tissue injury by activating non-immune 
cells at the tissue level. 
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7. Zusammenfassung 
Stimulation mit Non-CpG-DNA und 3P-RNA führte zu einer Toll-Like-Rezeptor-
unabhängigen Ausschüttung  proinflammatorischer Zytokine und Typ I Interferone in 
glomerulären Mesangialzellen. Beide Liganden induzierten vergleichbare 
Genexpressionsmuster in Mesangialzellen. Damit wurde die Existenz TLR-unabhängiger 
Signalwege und Produktion von Typ I Interferone in Mesangialzellen aufgedeckt. Dieses 
Ergebnis unterstützt die These, dass Immmunkomplexe, die mit Nukleinsäuren assoziiert 
sind, glomeruläre Zellen TLR-unabhängig aktivieren und zur Entzündungsreaktion im 
Glomerulus beitragen können. Des Weiteren veränderte die Exposition von Non-CpG-
DNA und 3P-RNA in MRLlpr/lpr-Mäusen die Krankheitsentwicklung der Tiere auf 
verschiedene Weise. Obwohl 3P-RNA und Non-CpG-DNA ähnliche Genexpression in 
Mesangialzellen induzierte, wurde die Erkrankung in vivo durch die Injektion beider 
Liganden unterschiedlich aggraviert. 3P-RNA induzierte Typ I Interferon-Signalwege und 
verminderte die Anzahl an regulatorischen T-Zellen, während Non-CpG-DNA Plasmazell-
Expansion, Lymphproliferation und Splenomegalie induzierte. Hingegen induzierten beide 
Liganden die Produktion von Autoantikörpern und eine vermehrte Ablagerung von IgG im 
Glomerulus. Diese Daten lassen vermuten, dass virale 3P-RNA und Non-CpG-DNA 
unterschiedlich Autoimmunität modulieren, beide Liganden jedoch den autoimmunen 
Gebeschaden durch aktivierte nicht-Immunzellen verstärken. 
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9. Abbreviations 
 
AIM2   Member absent in melanoma 2 
ANA   Antinuclear antibodies  
AP-1   Activator protein 1 
APC   Antigen presenting cell 
ATF   Activating transcription factor 
BCR   B cell receptor 
BMDC  Bone marrow dendritic cell 
BSA   Bovine serum albumin 
CAM   Cell adhesion molecule 
CARD   Caspase recruitment domain 
cDNA   Complementary DNA 
DC   Dendritic cell 
DEPC   Diethyl pyrocarbonate 
DMEM  Dulbecco’s modified Eagle’s medium 
DNA   Deoxyribonucleic acid 
DNTPs  Deoxynucleotide triphosphates 
ELISA   Enzyme-linked immuno sorbent assay 
FCS   Fetal calf serum 
FITC   Fluorescein isothiocyanate 
Flt3L   FMS-like tyrosine kinase 3 ligand 
GMCSF  Granulocyte-macrophage colony-stimulating factor 
HMGB1  High mobility group box protein 1 
IC   Immune complex 
IFN   Interferon 
Ig   Immunoglobulin 
IKK   Ikappa B kinase 
IL-1R   Interleukin 1 receptor 
IRAK   Interleukin-1 receptor associated kinase 
IPS-1   IFNβ promoter stimulator 1 
IRF   Interferon regulatory factor 
ITS   Insulin/transferrine/selenium 
JNK   C-jun N-terminal protein kinase 
LGP2   Laboratory of genetics and physiology 2 
LPR   Lymphoproliferative 
LPS   Lipopolysacharide 
MCP-1 (CCL2) Monocyte chemoattractant protein-1 
MDA5   Melanoma differentiation associated protein 5 
MHC   Major histocompatibility complex 
MIP-2 (CXCL2) Macrophage inflammatory protein 2 
MyD88  Myeloid differentiation protein 88 
MSU   Monosodium urate 
NALP3  NACHT-LRR-PYD–containing protein 3 
NADH   Nicotinamidadenindinukleotid 
NF-kB   Nuclear factor k B 
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NOD   Nucleotide-binding oligomerization domain 
ODN   Oligodeoxynucleotide 
PAMPs  Pathogen-associated molecular patterns 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PE   Phycoerythrin 
PI3K   Phosphoinositide 3-kinase 
PRR   Pattern recognition receptors 
PS   Penicillin/streptomycin 
RIG-1   Retinoic acid-inducible gene 1 
RNA   Ribonucleic acid 
RT   Reverse transcriptase 
SLE   Systemic lupus erythematosus 
Sm   Smith antigen 
SNP   Single nucleotide polymorphism 
snRNP   Small nuclear ribonucleoproteins 
ssRNA   Single stranded RNA 
STING  Stimulator of IFN genes 
TBK1   TANK binding kinase 1 
TIR   Toll interleukin like receptor domain 
TLR   Toll-like receptor 
TMB   3,3’,5,5’-tetramethylbenzidine 
TNF   Tumour necrosis factor 
TRAF   TNF receptor associated factor 
TRAM   TRIF-related adaptor molecule 
TRIF   TNF receptor-inhibitory factor 
WT   Wild type  
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Appendix 
 
1.FACS buffer: 
Sterile DPBS 500 ml  
Sodium azide 500 mg (0.1 % )  
BSA 1 g (0.2 %)  
 
2. 10X HBSS (Hank’s Balanced Saline Solution) with Ca, Mg:  
For 1000 ml 
KCl 4 g 
KH2PO4 0.6 g 
NaCl 80 g  
Na2HPO4.2H2O 0.621 g 
NaHCO3 3.5 g 
CaCl2 1.4 g (or CaCl2.2H2O 1.854 g) 
MgCl2.6H2O 1 g 
MgSO4.7H2O 1 g 
D-Glucose 10 g  
Dissolve in 900 ml of distilled water and adjust to pH 7.4 with 1N HCl or 1N NaOH. Make 
up the volume with distilled water to 1000 ml. 
 
3. 10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg: 
For 1000 ml  
KCl 4 g 
KH2PO4 0.6 g 
NaCl 80 g  
Na2HPO4.2H2O 0.621 g  
Dissolve in 1000 ml and autoclave. 
 
4. 50 % Glycerol in 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2: 
a). 0.48 g of Tris-HCl in 100 ml of distilled water, adjust pH to 7.4 (= 40 mM)  
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b). 50 ml of Glycerol 100 % + 50 ml of 40 mM Tris-HCl (20 mM)  
c). Add 100 ul of 1M MgCl2 solution. 
 
5. EDTA 2 mM: 
EDTA 7.44 mg in 10 ml HBSS (without Ca, Mg)  
To be preheated in 37 0C water bath before use. 
 
6. Anesthesia mixture: 
10 ml Midazolam (1 mg/ml)  
2 ml Fentanyl (0.05 mg/ml)  
1 ml Dormitor (1 mg/ml)  
 
7. Antagonist mixture: 
5 ml Annexate (0.1mg/ml)  
0.5 ml Antisedan (5 mg/ml)  
3 ml Naloxon (0.4 mg/ml)  
 
8. MACS buffer: 
PBS pH 7.2 0.5% BSA, 2 mM EDTA  
 
9. Citrate buffer: 
10X 110 mM Sodiumcitrate in ddH2O with 2N NaOH to pH 6  
 
10. PBS: 
2.74 M NaCl 54 mM KCl 30 mM KH2PO4 130 mM Na2HPO4 in ddH2O with HCl to pH 
7.5 
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